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1  Introduction 
 
1.1 The role of serotonin in long and short distance communication between cells  
 
For every properly functioning organism it is essential that its different organs as well as its 
single cells communicate and coordinate their functions.  
Communication between body organs or cells is not to be understood as conscious message 
transmission. Adjacent cells or cells of a remote organ react on stimuli from other cells in a 
predefined, distinct manner. These stimuli can be electrical in nature, chemical or mechanic. 
Organs can, on the one hand, react on a current biological condition of the organism that 
was caused by other organs in the first place. In case of this indirect “communication” an 
organ perceives the extent of a particular physiological parameter and responds with an 
appropriate adjustment of its cell functions. Accordingly, arterial baroreceptors in the human 
aortic arch for example recognize blood pressure changes as result of adrenaline rush during 
strong excitement and induce alteration of the force and speed of the heart´s contractions 
through the central nervous system. On the other hand, there are direct communication 
systems, which utilize messenger substances for directed transport of information. Thus, 
cells of particular organs can be informed about the activity- and metabolic state of the whole 
organism, the microenvironment and the need to activate, up- or downregeulate certain of 
their cell functions. This thesis discusses one of the most important and widespread 
messenger systems in mammals and two of its cellular receptors in particular: the 
serotonergic system with its receptors 5-HT1A and 5-HT7. Messenger substances are 
generally released by cells or glands in one part of the organism and convey their message 
to cells in other parts. This sort of long distance communication is termed endocrine 
signaling. Thereby, a particular messenger molecule affects only these cells, which express 
a certain receptor that is capable to receive and transmit the incoming signal. A messenger 
released from some part of the body can therefore directly control a single cells individual 
biological activity within the context of the organism as whole. Not only cells from different 
organs communicate with each other but also adjacent cells within one functional region can 
influence each other through messengers. Communication between cells via direct contact is 
called juxtacrine signaling while signaling over short distances is named paracrine. The 
messenger substances used for cellular signaling have been functionally classified as: 
hormones, growths factors, extra-cellular matrix components, cytokines, chemokines, 
neurotransmitters, neurotrophins and active oxygen species.  Serotonin is one representative 





as endocrine signaling as hormone in the human body. Both ontogenetically and 
phylogenetically the serotonergic system is one of the first neurotransmittersystems to 
manifest in mammalian central nervous systems (CNS) (Kriegebaum et al. 2010 a).  
The CNS is the anatomic correlate of the complex information processing network that 
enables the human body to accomplish and regulate autonomic vital processes as well as 
complicated cognition-, thinking- and movement processes. It contains the brain, spinal cord 
and retina and integrates the information that it receives from, and coordinates the activity of 
the peripheral nervous system (PNS). The PNS conducts collected information from the 
periphery via sensory (afferent) pathways to the CNS. The latter processes the gathered 
information and induces movements via motoric (efferent) pathways and nerves. The basis 
of CNS information processing is formed by nerve cells, neurons that connect to each other 
through synaptic interfaces to form networks. Receptors on the postsynaptic side receive 
information from presynaptic neurons or from adjacent glia cells. Receptors of a neuron are 
particular protein molecules to which one or more specific kinds of messenger substance, 
generally neurotransmitters may attach. Binding of these ligands then leads to a change 
and/or stabilization of a certain shape, the conformation of the receptor. Subsequently, this 
conformational change may trigger some sort of cellular response e.g. opening or closing of 
ion channels or initiation of an intracellular signaling cascade using second messenger 
molecules. Hence, cells can communicate over long distances or with cells in the vicinity via 
messengers, in this case either hormones or neurotransmitters which bind to the appropriate 
receptor of another cell.  As mentioned above the serotonergic system with its multifunctional 
messenger serotonin is one of the most important messenger systems and controls 
numerous core functions of the human body.  
 
1.2 Serotonin and its function in the human body  
 
This thesis is meant to further clarify the role and interaction of the two serotonin receptors 5-
HT1A and 5-HT7 within the complex serotonergic network. 
Serotonin, or 5-Hydroxytryptamine (5-HT), is a widely spread messenger substance in 
nature. Even single-celled organisms like entamoeba histolytica are reported to produce 
serotonin and use its features as an essential trigger of diarrhea in humans, seen in 
amebiasis (McGowan et al. 1983). Also plants are to count among the group of serotonin 
producing organisms. Thus serotonin in stinging nettles is jointly responsible for their known 
effect. Based on the fact that serotonin and its receptors already occur in such simple 





serotonergic systems evolved in the cryptozoic eon about 700-800 million years ago 
(Peroutka and Howell 1994). 
As Indolamine, 5-HT belongs like the three ketecholamines adrenaline (epinephrin), 
noradrenaline and dopamine as well as the neurotransmitter histamine to the group of 
monoamine neurotransmitters. Maurice Rapport was the first one to reveal its chemical 
structure in 1949 (Rapport 1949). Chemically it is based on an indole structure containing an 
amino group and a substituted hydroxyl group. (Fig. 1.1) 
 
 
Fig.1.1 structural formula of serotonin 
Modified according to Amit et al. (1978, P. 268) The figure shows the chemical structure of serotonin 
according to x-ray crystallographic determination; Molecular formula: C10H12N2O.  
 
In human metabolism, 5-HT is derived from the amino acid L-tryptophan by a short metabolic 
pathway consisting of two enzymes: tryptophan hydroxylase (TPH) and amino acid 
decarboxylase (DDC). (Fig. 1.3) In the body approximately 90% of the total serotonin 
amount, valued at 10 mg, is located in the enterochromaffin cells in the digestive tract. The 
remainder is found in neurons of the digestive nervous system and the CNS or in blood 
circulation. The name serotonin was derived from its presence in the blood serum where it 
regulates the tone of the bloodvessels. This function already constitutes an important effect 
on human homeostasis. As early as in the 1930s Vittorio Erspamer revealed that an extract 
from the enterochromaffin cells, which he named “enteramine”, made smooth muscle cells in 
the intestine contract. Over the years it became apparent that 5-HT is involved in a 
tremendous diversity of functions: regulation of the cardiovascular system and the blood 
pressure, (Hoyer et al. 1994) blood clotting, peristalsis of the digestive tract (Gershon 1999) 
and intraocular pressure modification (Costagliola et al. 2008). 
The impact of 5-HT in the CNS affects almost every brain function like cognition and 





regulation (Balcells-Olivero et al. 1998, Gilbert et al. 1988, Hjorth 1985, Seletti et al. 1995) 
sensors and pain perception, appetite, sexual behavior and hormone secretion to mention 
the most important aspects. Its influence on mood gave him the nickname happiness 
hormone.  
 
1.3 The serotonergic system in the CNS 
 
Investigation of the serotonergic network generally affects every cell system in the body that 
makes use of sorotonergic signal transduction. The purpose of this thesis might be 
particularly interesting for serotonin processes in the hippocampus, as hippocampal neurons 
have been found to coexpress the very two subtypes of serotonin receptors this investigation 
is dealing with: 5-HT1A and 5-HT7 (Bickmeyer et al. 2002, Neumaier et al. 2001, Azmitia et al. 
1996). It is also interesting that the respective expression levels of 5-HT1A and 5-HT7 in the 
hippocampus vary during development (Renner et al. 2012) and therefore interaction of the 
two receptors might be tuned differentially at distinct stages.  
Serotonergic neurons are mainly located in groups (raphe nuclei) paramedian of the brain 
stem. Raphe means ‘‘seam’’ and refers to the midline of the brain stem. These raphe 
complexes can be devided into two subgroups as related to their projection field. Raphe 
serotonergic neurons of the caudal brain stem, such as raphe magnus, raphe pallidus and 
raphe obscurus and parts of the adjacent lateral reticular formation form descending tracts 
and project prominently to the motoric and autonomous systems of the spinal cord. Fibers of 
raphe obscurus and pallidus exert an activating affect on anterior horn motor neurons of 
flexor and extensor muscle groups in the medulla. Serotonergic axons of raphe magnus 
terminate in the dorsal horn of the medulla. Here, released serotonin activates 
enkephalinergic interneurons which inhibit transmission of nociceptive stimuli (pain 
sensation) (Kriegebaum et al. 2010 a, Gulbins and Lang 2011). Nuclei of the rostral raphe 
complex are raphe pontis, raphe dorsalis, raphe medianus, raphe linearis caudalis and the 
nucleus tegmenti retikularis pontis. They principally project to the diencephalon and forebrain 
and terminate in neuron complex areas such as amygdala, cerebral cortex, striatum and 
hippocampus (Kriegebaum et al. 2010 a, Gulbins and Lang 2011). These structures 
constitute the anatomic correlates of complex neuronal networks that control many neural 
functions through integrated circuitry between each other. Serotonergic fibers are one part of 
this neuronal matrix and therefore involved in control of the core functions mentioned above, 
such as cognition and memory, circadian rhythm, temperature regulation, appetite, sexual 





Analysis of the interaction of the two 5-HT receptor subtypes 5-HT1A and 5-HT7 might be of 
special relevance to hippocampal neurons, which have been shown to coexpress these 
receptor subtypes. The hippocampus is a major brain structure in the temporal lobe of the 
cerebral cortex and is made up of three subunits, namely Ammon´s horn (hippocampus 
proper), dentate gyrus and subiculum. The hippocampal formation stretches from the 
amygdala to the splenium of the corpus callosum and is laterally limited by the inferior horn 
of the lateral ventricle (Kleine and Rossmanith 2009). Functionally, the hippocampus is 
responsible for the transfer of declarative memory from short-term to long-term memory. In 
this regard the hippocampus is traditionally widespread mentioned as part of the Papez 
circuit, an early concept of the memory storing system. Later the hippocampus was 
considered to be a part of the limbic system, a likewise obsolete concept of brain structures 
with a particular set of functions. The hippocampus also plays an important role in spatial 
orientation and in emotion. Thus depression seems to reduce the hippocampal volume 
(Campbell and Macqueen 2004). It receives input from different sensory systems, which gets 
processed and send back to the cortex. (Fig.1.2) The major input unit of the hippocampal 
formation is the entorhinal cortex, which is assigned to the parahippocampal regions. It 
obtains sensory and motor information from several areas of temporal, frontal, olfactory and 
midline cortices, amygdala, claustrum, thalamus and the mammillary complex. Other input 
originates from the medial septal nucleus via fornix (Casas and Tranel 2008). The focus, 
considering the actual thesis, is on serotonergic input from raphe nuclei besides other 
brainstem nuclei input as e.g. noradrenergic fibers from locus coeruleus. The entorhinal 
cortex subsequently conveys the information to the dentate gyrus which forwards it to 
hippocampus proper. Several feedback loops and local projections of interneurons modify 
the information flow in the hippocampal formation. The subiculum constitutes the major 
output entity of the formation. It sends information to cingulate, retrosplenial and frontal 
cortex areas as well as to thalamic nuclei, hypothalamic nuclei, amygdala and the 







Fig. 1.2 Hippocampal signaling 
Modified according to Lang and Lang (2007, P. 449) The scheme illustrates the circuitry between the 
different neuronal domains in the brain involved in learning and formation of memory in relation to the 
hippocampus.  
  
The serotonergic fibers terminating in the hippocampus are among other things believed to 
affect the learning process as well as emotional regulation and anxiety (Kriegebaum et al. 
2010 b). Accordingly, the serotonergic system is regarded as the focus of current hypotheses 
on the pathogenesis of disorders with the shared feature of emotional dysregulation.  
 
1.4 Serotonin receptors and signaling cascades on molecular level 
 
Serotonin functions via at least 14 different classes of serotonin receptors also known as 5-
HT receptors (5-HTR). The purpose of the actual thesis is to examine the interaction 
between the serotonin receptor subtypes 5-HT1A and 5-HT7 and their mutual impact on 
cellular signal transduction. For the serotonergic network is far more than just the sum of its 





Except the 5-HT3 receptor group which gate a cation-permeable ion channel, all 5-HT 
receptors are G protein coupled receptors (GPCRs). GPCRs constitute one particular cellular 
transmission mechanism which will be explained in detail in the following chapter. In order to 
classify the 5-HT receptors in a more systematic manner they can be divided in 7 receptor 
families termed 5-HT1 up to 5-HT7. These families can be subdivided into diverse subtypes 
which together make up the 14 different receptors. Each receptor can be attributed a 
particular set of preferential ligands, main localization and major pathways as well as 
physiological impact.  
“Although there are no absolute distinctions between 5-HT receptors in their signaling 
modes, and no individual subtype possesses just one single transduction mechanism”, 
(Millan et al. 2008, P. IV) there are certain general tendencies regarding the function of the 
different receptors, which are worth mentioning (Fig. 1.3). The 5-HT1 receptor family 
represents with its subtypes 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1e and 5-HT1F the biggest subgroup 
of serotonin receptors. These receptors collectively inhibit the creation of the cellular second 
messenger cyclic adenosine monophosphate (cAMP) via Gi/o proteins. The enzyme adenylyl 
cyclase (AC) converts adenosine triphosphate to cAMP under the control of either stimulating 
(Gs) or inhibiting (Gi/o) G proteins. (see below) cAMP in turn stimulates the cAMP-dependent 
protein kinase A (PKA) which downstream can phosphorylate manifold effector proteins. 
Moreover cAMP has been shown to activate the family of GTPase exchange factors Epac1-2 
(exchange protein directly activated by cAMP) (De Rooij et al. 1998) that subsequently 
activate small Ras-like GTPase proteins, such as Rap1 or Rap2. Functionally, cAMP 
signaling mediates diverse cellular responses throughout the body involved in the regulation 
of processes such as cardiac contraction, insulin secretion and neurotransmitter release in 
neurons, many of which are found to be modulated via both pathways PKA- and Epac-
mediated (Gloerich and Bos 2010). 
The 5-HT2 triplets (A,B and C) share recruitment of phospholipase c via Gq/11 as their primary 
mode of signaling. 5-HT2A receptors play an important role in blood clotting in thrombocytes. 
5-HT2B receptors are reported to be associated with diseases like migraine and chronic 
hypertension whereas 5-HT2C receptors are shown to be linked with regulation of eating- and 
sexual behavior in the CNS. The K+ and Na+ selective ion channel 5-HT3 is revealed to be a 
highly effective target for antagonists to suppress cytostatics induced vomiting. The receptor 
families 5-HT4, 5-HT6, 5-HT7 all stimulate AC via Gs G proteins. The two 5-HT5 subgroups A 







Fig. 1.3 Principal serotonergic signaling cascades  
Modified according to Millan et al. (2008, P. 455). The figure depicts the biosynthesis of serotonin in 
neuronal cells in two enzymatic steps and its deactivation by monoamine oxidase A (MAO-A) after 
release and reuptake through serotonin transporters (SERT). Moreover the main targets of serotonin 
are displayed and also the downstream signaling cascades with the involved messengers in adjacent 
cells. 5-HT inhibitory autoreceptors are localized presynaptically. 5-HT receptor activation in non-
neuronal cells can lead to release of further modulators. The scheme does not claim any 
completeness. Abbreviations: 5-HIAA, 5-hydroxyindole amino acid; DAG, diacylglycerol; DDC, amino 
acid decarboxylase; D-Ser, D-serine; EPAC, exchange protein directly activated by cAMP; ERK 1,2, 
extracellular signal regulated kinases; GIRK, G protein coupled inward rectifier potassium channel;  
Glu, glucose; Gly, glycine; GlyT1, glycine transporter; IP, inositol phosphate; MAP, mitogen activated 
protein kinases; NO, nitric oxide; PIP2, phosphoinositol bisphosphate; PKA, protein kinase A; PKC, 
protein kinase c; PLC, phospholipase c; Rap1,2, small Ras-like GTPase proteins; SRE, serum 
response element; TPH, tryptophan hydroxylase; VMAT, vesicular monoamine transporter 
 
1.4.1 General structure and mechanism of GPCRs 
 
The understanding of the basic structure and modes of action of the receptors examined is 
required for developing hypotheses about their interaction.   
Except the 5-HT3 receptor all 5-HT receptors belong to the family of G protein-coupled 





in 6 classes A (Rhodopsin-like), B (Secretin receptor family), C (Metabotropic 
glutamate/pheromon), D (Fungal mating pheromone receptors), E (Cyclic AMP receptors) 
and F (Frizzled/Smoothened) (Attwood and Findlay 1994). 5-HT receptors belong to class A 
which is by far the largest. In general, GPCRs are composed of a single-polypeptide chain 
that has seven membrane-spanning domains with three intracellular and three extracellular 
loops of amino acids (Fig.1.4). The amino- terminal end of the protein is extracellular and the 
carboxyl- terminal end is located in the cytoplasm. Often extracellular loop two covers the 
cavity formed by the remaining helices, serving as a modulator for ligands to attach to the 
binding domain (Cherezov et al. 2007). Intracellular loop three constitutes the binding- and 
activation-domain for signaling molecules like G proteins and therefore has a determining 
influence on receptor-G protein specificity (Rosenbaum et al. 2007).   
 
 
Fig. 1.4 Morphology of G protein-coupled receptors 
Schematic illustration of GPCRs showing the seven hydrophobic membrane-spanning domains 
(numbered I-VII) with three intracellular and three extracellular loops of amino acids. The amino-
terminal end (NH2) is located extracellular while the carboxyl-end (COOH) is intracellular. Extracellular 
loop two spans the receptor cavity and intracellular loop three is responsible for G protein binding.  
 
Basically, upon ligand binding GPCRs undergo a conformational shift which results in the 
activation of the associated G protein that represents the transduction element between the 





The conformational change leads to a rearrangement of the transmembrane domains of the 
GPCR, thereby passing different energetic levels. These changes are not understood in 
detail so far. Several scenarios are conceivable. Upon binding agonists might disrupt 
intramolecular interactions that stabilize the inactive state of the receptor or agonists could 
stabilize a more active state by serving as bridges that create new interactions between 
transmembrane domains (Kobilka and Deupi 2007). Discussing the different energetic states 
and functional states, respectively, of GPCRs, it is necessary to clarify the nature of these 
distinct modes. GPCRs in general, except the light absorbing rhodopsin, have more than two 
activity levels. GPCRs possess a whole continuum of various functional activity states 
reaching from no activity to maximum activity. Different ligands may favor distinct 
conformational states which in turn determine different functional states (Kobilka and Deupi 
2007). Many GPCRs have a certain agonist independent basal activity. Pure “agonists” fully 
activate the receptor by definition, whereas “partial agonists” induce submaximal activation. 
“Inverse agonists” suppress basal activity. The activated receptor subsequently causes a 
conformational change of the attached G protein, resulting in the exchange of the G protein 
bound guanosine diphosphate (GDP) with guanosine triphosphate (GTP). The heterotrimeric 
G protein then dissociates from the GPCR and splits up into the active GTP bound Gα 
subunit and the Gβγ dimer. These subunits activate primary effectors which modulate ion or 
second messenger concentrations as for example cAMP generated by AC. Gα subunit 
activity is terminated by hydrolyzation from GTP to GDP and Gα can reassociate with a Gβγ 
unit to enter a new signaling cycle. Thus, the system allows for a high degree of amplification 
of the signal. There are different types of Gα subunits such as Gsα (G stimulatory), Giα (G 
inhibitory), Goα (G other), Gq/11α, and G12/13α. Traditionally, the Gβγ unit was sparsely noted 
and seen as a passive, inhibiting modulator of Gα subunits effectors. Nowadays it is known 
that the Gβγ subunit impacts on various effectors such as AC (see below), phospholipase C, 
(Nielsen et al 1991, Camps et al. 1992) phospholipase A2, phosphoinositide 3-kinase 
(Stephens et al. 1994), G protein coupled inward rectifier potassium (GIRK) channels 
(Logothetis et al. 1987) and the beta-adrenergic receptor kinase (Krapivinsky et al. 1995). 
Besides multifaceted mutual crosstalk and G protein unselectivity (discussed below), diverse 
post-translational modifications constitute a common way of receptor regulation. GPCRs 
possess multiple intracellular sites susceptible to phosphorylation. Different enzymes like 
PKA, PKC or GPCR kinases (GRK) are able to attach negatively charged phosphor to the 
receptor, leading to conformational change and consequently attenuated signaling due to 
blunted G protein coupling (Tobin 2008). Furthermore, phosphorylation can trigger β-arrestin 
binding to the receptor. β-arrestins serve as scaffolds for many proteins as clathrin or MAP 





in the fashion of receptor down regulation in order to allow desensitization after prolonged 
receptor stimulation. Interestingly, Gα protein subunits can also be phosphorylated, further 
tempering signal transduction (Hensler 2003). Another important modification is receptor 
glycolisation. N-asparagine glycolisation for example is required for 5-HT1A plasma 
membrane expression (Dutton et al. 2008). 
Moreover the covalent attachement of palmitic acid to the C-terminus of GPCRs represents a 
common receptor modification, impacting receptor function, trafficking and especially 
receptor accumulation in lipid rafts as it is required for efficient signaling (Resh 2006). 
Collaborating groups have shown that 5-HT1A receptors are stably palmitoylated and 
palmitoylation is necessary for 5-HT1A G protein coupling (Kobe et al. 2008).  
 
1.4.2 The 5-HT1A receptor 
 
The 5-HT1A receptor is the most widespread of the serotonin receptors. Its counter-
cooperative impact on cellular cAMP makes it an interesting object of investigation in 
combination with its opponent, the 5-HT7 receptor. Besides serotonin 5-HT1A receptors can 
be activated by 5 carboxamidotryptamine (5-CT) (Yamada et al. 1998). It is expressed in the 
cerebral cortex, hippocampus, raphe nuclei, septum, and throughout the brainstem, to 
mention the main loci (Azmitia et al. 1996, Kia et al. 1996). Most of the 5-HT1A receptors in 
the raphe nuclei are somatodendritic autoreceptors being involved in receptor signaling via 
negative feedback cycles. In other regions such as the hippocampus, the 5-HT1A receptor is 
located postsynaptically. Functionally, the 5-HT1A receptor affects a huge number of 
physiological phenomena; partially neuro-endocrine functions and partially peripheral effects. 
The receptor is involved in thermoregulation  (Balcells-Olivero et al. 1998, Gilbert et al. 1988, 
Hjorth 1985, Seletti et al. 1995) and central down-regulation of blood pressure and heart rate. 
Receptor activation in rostral ventrolateral medulla neurons trigger peripheral vasodilation 
contributing to pressure regulation and body temperature via heat dissipation (Dabiré 1991).  
5-HT1A activation has been reported to affect immune function by elevating B-lymphocyte 
proliferation (Iken et al. 1995). Moreover, the 5-HT1A receptor is strongly associated with 
memory and cognition whereby receptor agonists have generally been shown to impair 
learning by interfering with memory-encoding mechanisms (Edagawa et al. 1998, Ogren et 
al. 2008). Apart from that, 5-HT1A activation has been revealed to reduce aggressive 
behavior (Miczek et al. 1998). Neuro-endocrinologically, 5-HT1A activation triggers secretion 
of manifold hormones like cortisol, corticosterone, adrenocorticotropic hormone (ACTH), 






 An important role in pathologic states and disorders like depression, schizophrenia, anxiety, 
(Toth 2003) Alzheimer´s Disease and also ischemic stroke, (Kamei et al. 2001) is attributed 
to 5-HT1A dysfunction which is reflected in the huge amount of medications targeting this 
receptor. Most drugs are aimed at increasing the general serotonin level in the synaptic cleft 
which has been shown to be a major effect in the treatment of depression. This can be 
achieved by supplementation of serotonin precursors like L-tryptophan and 5-HTP, serotonin 
reuptake inhibition by selective serotonin reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tetracyclic 
antidepressants (TeCAs) or by monaminoxidase inhibition (MAOIs). Another way of elevating 
serotonin effects is direct 5-HT1A agonism as for example azapirones do, commonly used as 
augmentation to other antidepressants.  
Regarding the molecular 5-HT1A mechanisms, activation of both the presynaptical and the 
postsynaptical receptors leads to neuronal hyperpolarization. Subsequently, this leads to 
reduced neuronal firing of raphe nucleus fibers as well as release of 5-HT from terminals in 
the respective projection areas (Hjorth 1985). In addition to inhibiting AC via Gi/o proteins and 
reducing cellular cAMP (Nebigil et al. 1995, De Vivo and Maayani 1986) 5-HT1A receptors 
trigger the opening of inwardly rectifying K+ (GIRK) channels via Gβγ subunits (Andrade and 
Nicoll 1987, Penington et al. 1993) and the inhibition of (N and P/Q-type) Ca2+ channels 
(Penington and Kelly 1990, Singh et al. 1996). Moreover, the 5-HT1A receptor activates the 
amiloride-sensitive Na+/H+ exchanger (NHE) via Gi/o which regulates cellular volume and pH 
(Magro et al. 2007). The receptor also acts via the Gz protein to increase the secretion of 
various neuroendocrine hormones (Serres et al. 2000). In the hippocampus, 5-HT1A 
receptors are mainly present in the CA1 subregion. Here they exert influence on glutamergic 
functions via action on NMDA and AMPA receptors in pyramidal cells and by changing the 
activity of GABAergic interneurons (Ogren et al. 2008). Thus, serotonin serves as modulator 
especially for declarative memory tasks such as contextual, spatial learning. Recent 
molecular modeling of the 5-HT1A receptor show that it is distinguished from the general 
GPCR structure among others by a considerably longer third intracellular loop which is 
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Table 1.1 Coupling patterns 5-HT1A and 5-HT7 
Modified according to Millan et al. (2008, P. 457). The table illustrates the main G protein coupling 
partners and principal signaling pathways of the serotonin receptors 5-HT1A and 5-HT7 without any 
claim to completeness. Abbreviations: (-), inhibition; (+), stimulation; Cx, cortex; DRN, dorsal raphe 
nucleus; Ecx, entorhinal cortex; g, channel; Hip, hippocampus; Hyp, hypothalamus; IH, 
hyperpolarisation-activated current; L,N,P/Q, types of Ca
2+
 channel; p, phosphorylated; Ras, Rap1, 




1.4.3 The 5-HT7 receptor 
 
The 5-HT7 receptor is the second object of study in this two receptor approach. It was first 





nucleus of the ventral hypothalamus, (Hedlund 2009) in thalamus, cortex and hippocampus. 
Besides, it is expressed in the gastrointestinal tract and in the vasculature, where it causes 
smooth muscle relaxation. The 5-HT7 receptor is integrated in a variety of physiological 
functions such as learning and memory, hippocampal signaling, thermoregulation and 
circadian rhythm (Duncan et al. 1999, Lovenberg et al 1993, Hedlund 2009, Sprouse et al. 
2004, Thomas et al. 2003) and disorders like depression (Hedlund 2009, Guscott et al. 
2003). The 5-HT7 receptor is linked to G-proteins Gs (Bard et al. 1993, Tsou et al. 1994) and 
G12 (Kvachnina et al. 2005). Activation of Gαs results in stimulation of AC and consequently in 
an increase of cyclic adenosine monophosphate (cAMP), which downstream activates 
protein kinase A (PKA), cAMP guanine nucleotide exchange factors (Epac1 and Epac2) and 
other cAMP dependent target molecules (eg. CNG-channels, CREB). Downstream, the 
cAMP-PKA signal transduction activates mitogen activated protein (MAP) kinases and 
extracellular signal regulated kinases (ERK) 1 and 2, whereas the latter seems also to be 
activated by the Epac pathway (Lin et al. 2003). G12 protein signaling causes activation of a 
serum response element (SRE) - mediated gene transcription via small GTPases, 
conceivably affecting neurite length and cyto-architecture (Kvachnina et al., 2005) (Tab. 1.1). 
 
1.5 Serotonin networks 
 
Messenger systems, such as the serotonergic system, are manifold, highly branched and 
deeply interconnected with other mediators. It is their nature as network to be influenced by a 
multitude of effectors and that a signal once initiated gets repeatedly converted and ramified 
in what is at the end a change of cell activity whatsoever. In these premises influences can 
be synergistic or antagonistic on certain signaling nodes. In the complex 5-HT messenger 
system different cellular configurations can be distinguished. Signal transduction involves 
multiple convergent inputs onto common integrative signals, which themselves display 
divergent (multiple) outputs. Released serotonin affects multiple receptors as for example 5-
HT1A and 5-HT7. Their signals converge on the same mediator, AC which gets inhibited and 
activated, respectively. Other receptors such as 5-HT7 and 5-HT4 synergistically activate AC. 
The counter-cooperatively mode of 5-HT1A and 5-HT7 illustrates the balanced control as 
universal feature of complex (signaling and supra-cellular) networks that is fundamental to 
homeostasis and favors resistance to disruption (Millan 2006). The AC constitutes another 
key link that controls the downstream targets PKA and Epac; this is termed pleiotropy 
(divergence/multiple roles). Other modes of network signaling also show modes of 
divergence and convergence such as bi-parallel, where 2 mediators mutually affect 2 targets 





points just to converge again on the subsequent level. Other configurations are the features 
of negative or positive feedback loops or fast-forward signaling in which a transmitter can 




Fig. 1.5 Modes of network signaling 
From Millan et al. (2008, P. 460). This model shows different kinds of messaging configurations on the 
basis of serotonin-signaling. Green circles represent the respective levels of sorotonergic pathways, 
whereby the number in each top circle corresponds to the respective 5-HT receptor. Abbreviations: 
DAG, diacylglycerol; Epac, exchange protein directly activated by cAMP; ERK, extracellular signal 
regulated kinases; Fyn, non receptor tyrosine kinase; GIRK, G protein coupled inward rectifier 
potassium channel; PKA, protein kinase a; PKC, protein kinase c; TK, tyrosine kinase;  
 
But this is just where the promiscuity starts. On top of these well known features of a network 





canonical GPCR pathways are not at all as strict and distinct as they were believed to be. 
Interference occurs on many levels of signal transmission, leading to bifurcations and 
providing higher sensitivity when opposing mediators e.g. GPCRs control certain effector 
concentrations (Milligan 1993). 
 
1.5.1 Promiscuity in 5-HT signaling pathways 
 
Interference and receptor cross-talk emerge on every level of signal transduction. When 
investigating a model of two receptors, as in this case 5-HT1A and 5-HT7, out of a complex 
messenger system it is essential to reflect about the different junctions within the signaling 
pathways with regard to the preliminary end product, cAMP. As precondition, when 
investigating promiscuity in 5-HT pathways, it is necessary always to analyze the same 
variant of a certain receptor. There can be considerable genetic diversity in receptors that 
respond to the same hormone or neurotransmitter and such genetic subtypes may be 
coexpressed in a single cell (Andressen et al. 2006). Different splice variants, editing variants 
and other polymorphisms which can be formed during the processes of transcription, 
translation and posttranslational modification (protein biosynthesis), can lead to multiple 
pharmacologically similar receptor subtypes, each of which is more selective for certain 
pathways (Milligan 1993). For the 5-HT1A receptor no splice variants are known and the gene 
is intronless (Hannon and Hoyer 2008). Two polymorphisms, Glycerin22 to Serin and 
Isoleucine 28 to Valine, have been found to alter the extracellular amino terminal region of the 
receptor68 (Nakhai et al. 1995). For the 5-HT7 receptor four different splice variants are 
known (5-HT7a – 5-HT7d) which differ in their C-termini (Heidmann et al. 1997). Nevertheless, 
no differences regarding pharmacology, signal transduction or tissue distribution have been 
found to date among these isoforms. Another feature termed “functional selectivity” 
enhances the complexity of 5-HT signaling. In general this means the ligand dependent 
selectivity for certain signal transduction pathways in one and the same receptor. Thus, 
Dimethyltryptamine (DMT) for example activates phospholipase A2 through 5-HT2A- and 5-
HTC - receptors whereas serotonin causes phospholipase C activation through these 
receptors (Berg et al. 2005). This effect may explain the phenomenon that direct 5-HT2 
agonists have psychedelic effects, in contrast to compounds that indirectly increase 
serotonin signaling at the 5-HT2 receptors, such as SSRIs. Accordingly, 5-HT1A receptor 
agonists show dissimilar efficacies at diverse Gα protein isoforms (Gi2 versus Gi3) and at the 
GIRK channels (Heusler et al. 2005, Raymond et al. 2001). A further mode of cross-talk is 
the above mentioned feature of phosphorylation. Since colocalized receptors can mutually 





signaling, this is an important mechanism of interconnection. As pointed out earlier 
phosphorylation can also result in receptor down regulation in the cell membrane through β-
arrestin binding.  
In addition, common protein partners like regulators of G protein signaling (RGS) constitute a 
potential mode of cross-talk. RGS accelerate GTPase activity and thereby promote GTP 
hydrolysis by the alpha subunit of G proteins. Ultimately, this leads to earlier determination of 
signal transduction (Gu et al. 2007). RGS also facilitate constitutive activity (coupling to Gi) of 
5-HT1A receptors (Seifert and Wenzel-Seifert 2002). As pointed out earlier, the Gβγ subunit 
undertakes crucial functions in 5-HT signaling. Since Gα protein coupling to the Gβγ dimer 
shows little selectivity the shared pool of Gβγ subunits may result in a form of cross-talk 
between 5-HT receptors (Woehler and Ponimaskin 2009). With regard to the topic of this 
thesis it is particularly interesting, that Gβγ subunits have been found to do both activating 
and inhibiting AC (Nielsen et al. 1991). Nevertheless, these findings have been made under 
very special conditions which are not applicable to the actual thesis and are going to be 
discussed in detail below. 
Additionally, signaling can take diverse paths dependent on the amount of available ligand. 
Accordingly, Eason et al. observed α2-adrenergic receptor coupling to Gi proteins at low 
agonist concentrations while binding to Gs proteins at high agonist concentrations (Eason et 
al. 1992). This implies a further important feature of 5-HT pathways; GPCR coupling to 
different G proteins. Based on the Gi – Gs mediated antagonism of the 5-HT receptors 5-HT1A 
and 5-HT7, the degree of selectivity for these G proteins is immensely important to evaluate a 
common impact on cell activity.  
Many GPCRs have the ability to interact and transduce signal through a variety of G-
proteins, (Woehler et al. 2010) although receptors have distinct preferences in their G protein 
selection. Thus, the three α2 adrenergic receptors α2A-C display cholera toxin and pertussis 
toxin sensitive dual coupling to Gi and Gs, respectively (Eason et al. 1992). In these 
premises, cholera toxin is known to inhibit Gs protein signaling whereas pertussis toxin blocks 
Gi signal transduction. Moreover, the human thyrotropin receptor is even capable of signaling 
trough members of all four G protein families (Laugwitz et al. 1996). Also the 5-HT4 receptor 
turned out to transduce signal through both Gi and Gs (Pindon et al. 2002). A further cross-
linking occurs as a consequence of the phenomenon of GPCR oligomerization which can 
influence signaling patterns of ligand bound receptors in distinct ways and therefore augment 
the diversity of GPCR functions in many cases (Maggio et al. 2005, Rios et al. 2001, Urban 
et al. 2007, Renner et al. 2012). Hence, George (George 2000) and Gomes et al. (Gomes et 
al. 2000) revealed that µ- and δ-opioid receptors form heterodimers and thereby generate a 





potency and rank order of highly selective synthetic agonists for each receptor were changed 
in HEK293-cells co-expressing both receptors, but also that agonists and antagonists of one 
receptor can positively augment the efficacy and potency of the agonist of the associated 
receptor. Correspondingly, Rocheville (Rocheville 2000) demonstrated that the dopamine 
receptor D2R and the somatostatin receptor SSTR5 hetero-oligomerize and synergistically 
inhibit AC. Here, stimulation and inhibition of SSTR5 directly influence the D2R pathway 
before the G-protein decoupling step. In constitutive receptor complexes trans-inhibitory 
effects might occur, so that specific blockade of each respective receptor effectively blocks 
downstream signaling and trafficking of both receptors simultaneously, which was observed 
in case of β-adrenergic receptors (βARs) and angiotensin II type 1 receptors (AT1Rs) (Barki-
Harrington 2003). Many serotonin receptor subtypes, like 5-HT1A, 5-HT1B, 5-HT1D, 5-HT4 and 
5- HT2C also tend to form dimers or oligomers (Lee 2004, Woehler and Ponimaskin 2009, 
Kobe et al. 2008). Collaborating groups even showed that the receptor subtypes 5-HT1A and 
5-HT7 hetero-oligomerize in vitro and in vivo and that hetero-oligomerization alters the 
functional behavior of the two receptors (Renner et al. 2012). Due to the manifold options of 
receptor interaction and cross-talk it seems likely that 5-HT7 and 5-HT1A receptors also 
interact on different levels of their signal cascades.  
 
1.6 Goal of thesis 
 
The serotonin receptor subtypes 5-HT7 and 5-HT1A work counter-cooperatively on the same 
effector, adenylyl cyclase (AC), via Gs- and Gi proteins respectively. Both receptors are 
expressed in CA1 hippocampal neurons (Bickmeyer et al. 2002, Neumaier et al. 2001, 
Azmitia et al. 1996, Kia et al. 1996) and in the prefrontal cortex, where they are reported to 
play a key role in the postnatal development (Béique et al. 2004). Cooperating groups have 
detected both receptors within the same neuronal cells (Renner et al. 2012). Fig. 1.6 shows 
neurons and glia cells of the pre-Bötzinger complex that express both receptors 







Fig. 1.6 5-HT1A – 5-HT7 coexpression in neurons and glia cells of the pre-Bötzinger complex  
Kindly provided by Dr.Dr. Till Manzke. The picture shows rodent neurons and glia cells in the pre-
Bötzinger complex labeled with fluorescent antibodies against 5-HT1A- (red, top line, left), 5-HT7- (blue, 
top line, middle) and GlyT2 receptors (green, top line, right). White arrows in the bottom line picture 
indicate cells which coexpress 5-HT1A and 5-HT7.  
 
The physiological occurrence of both receptors in the same cells raises the question how 
their contrary influences merge on the adenylyl cyclase. The work in hand shall characterize 
the 5-HT1A-5-HT7 receptor interaction with regard to the cAMP concentration as a quantity to 
be measured. As low levels of cAMP primarily activate PKA whereas higher levels favor 
Epac activation, (Murray et al. 2009) [cAMP] determines the major downstream pathway. 
Mutual signal extinction, privilege of one pathway or a phase-shifted signal as result of 5-
HT1A-5-HT7 cross-talk are conceivable. A live imaging FRET approach for cAMP 
concentration measurements was chosen so that single cells could be taken for analysis, 
which coexpressed both receptors. This method allowed observing cAMP production under 
physiological conditions. 
 




2 Material and methods 
 
2.1 FRET imaging 
 
Classical approaches to analyze receptor-mediated changes in intracellular [cAMP] so as 
radioactive tracking of ATP metabolism cannot provide exact, quantitative information in high 
temporal and spatial resolution within single cells. In this thesis Förster resonance energy 
transfer (FRET) between two fluorophores was used to determine the real-time course of 
cAMP levels upon receptor stimulation in living cells. In this kind of energy transfer a donor 
fluorophore (D) is excited by light of the appropriate wavelength and, in its electronic excited 
state, transfers energy when falling back in its basal state to an acceptor (A) fluorophore 
through nonradiative dipole-dipole coupling. Therefore these two fluorophores have to be in 
very close proximity. The transfer results in excitation of A. Subsequently, the induced 
fluorescence emission both from the donor as well as from the acceptor can be measured. 
To apply this energy transfer on [cAMP] measurements a special biosensor was taken which 
uses the cAMP activated GTPase exchange factor Epac1, (De Rooij et al. 2000, Ponimaskin 
et al. 2007) as backbone. This approach is based on a special FRET pair tandem construct 
and a measuring method first described by Adams et al. (Adams et al. 1991). Ponsioen et al. 
(Ponsioen et al. 2004) applied this method on the described Epac construct which was then 
further developed in this department and by collaborating groups (Salonikidis et al. 2008, 
Salonikidis et al. 2011). The Epac1 based construct (in the following called “CEPAC*”) is 
fused to the fluorophore mCerulean (D) (Rizzo et al. 2004, Rizzo et al. 2006) at its amino 
terminus, whereas the carboxy terminus is fused to mCitrine (A) (Griesbeck 2001). In 
addition, the DEP domain which is responsible for membrane localization of Epac1 was 
deleted and inserted mutations prevent Rap1 activation (Ponsioen et al. 2004). cAMP 
binding at the cAMP binding domain induces a conformational change of the Epac1 protein, 
resulting in a distance and/or orientation change between the fluorophores of the FRET pair. 
Consequently, the energy transfer between the two fluorophores is interrupted and the 
intensity ratio between donor and acceptor emission changes (Fig. 2.1). A reduction of 
intracellular cAMP therefore increases the energy transfer between mCerulean and mCitrine 
while a [cAMP] rise diminishes FRET (Ponsioen et al. 2004, Ponimaskin et al. 2007). 
 






Fig. 2.1 Förster resonance energy transfer of the CEPAC* tandem construct 
Modiefied according to Bos (2003, P. 734) and Ponsioen et al. (2004, P. 1177). The model shows a 
conformational change of the FRET-sensor-construct (Donor-Epac (δDEP-CD)-Acceptor) induced by 
cAMP binding to the regulatory domain of EPAC. The distance between the two fluorophores 
increases after cAMP-binding, resulting in a decrease of FRET intensity.  Consequently, an increase 
of FRET intensity (EfDA/γ) corresponds to a decrease of intracellular [cAMP].  Abbreviations: EPAC, 
exchange protein directly activated by cAMP; CEPAC*, FRET-sensor-construct using mCerulean and 
mCitrine as FRET-pair, D, donor; A, acceptor.  
 
As the model shows, the FRET-sensor-construct (CEPAC*) can be in two states of FRET 
efficiency (E1 and E2). Due to binding or unbinding of cAMP the fraction (fDA) of CEPAC* 
molecules in a higher FRET state changes and consequently the apparent FRET efficiency 
ΔEfDA of the total amount of biosensor molecules (with ΔE = E1 - E2). The FRET value ΔEfDA 
of CEPAC* becomes a function of the cAMP concentration present. Measuring the emission 
spectra at both D- and A- excitation wavelengths in three different filter sets allows [cAMP] 
detection in a quantitative manner over the course of time.  
  
2.1.1 Construction of expression plasmids 
 
The plasmids that encode for mCerulean and mCitrine were obtained from ADDGENE. The 
coding sequences were amplified by PCR introducing recombinant recognition sites for 
restriction enzymes using the primers: mCerulean-for (5’- -3’), mCerulean-rev (5’- -3’), 
mCitrine-for (5’- -3’) and mCitrine-rev (5’- -3’). The resulting PCR products were subcloned 
into the mammalian expression vector pTarget (PROMEGA), which served as positive control 
in FRET measurements. mCerulean and mCitrine were isolated  from these vectors with the 
restriction enzyme pairs NotI/EcoRV and NheI/EcorI (NEW ENGLAND BIOLABS), respectively,  
 




and cloned into the corresponding sites in the vector pcDNA3.1-CFP–Epac(δDEP-CD)–YFP, 




The FRET experiments were done with an upright epifluorescence microscope, equipped 
with a water immersion objective (XLUMPlanFI, 20×, NA 0.95, OLYMPUS, Germany). The 
exciation light came from a 100 W xenon lamp attached to a monochromator (OPTOSCAN, 
KINETIC IMAGING) which was coupled to the microscope via fibre optics. The experimental 
setup and evaluation required the use of two excitation wavelengths that were 420/10 nm (λ1) 
and 510/10 nm (λ2), called donor and acceptor excitation, respectively. A dichroic mirror 
(505 nm) was taken to separate emission from excitation light and passed the light into the 
objective pathway to excite the specimen. According to its properties, the higher intensity of 
the second excitation wavelength was much less reflected and thus, similar intensities were 
obtained at the two excitation wavelengths, 420/10 nm and 500/10 nm. Using a DUALVIEW 
(OPTICAL INSIGHTS, Tucson, Arizona, USA), the fluorescence emission signal was split by a 
dichroic mirror (515 nm) into 470/30 nm for the donor channel and 535/30 nm for the 
acceptor channel. With an IXON camera DV887DCS (ANDOR TECHNOLOGY, South Windsor, 
CT, USA), three principle images were acquired: (a) the donor image at donor excitation and 
donor emission wavelength, (b) the FRET image at donor excitation and acceptor emission 
wavelength, (c) the acceptor image at acceptor excitation and acceptor emission wavelength. 
The excitation exposure times should not be too long to avoid bleaching of the fluorophores. 
On the other hand they have to be long enough depending on the fluorophore expression 
and emission intensities of the cells. Times about 1 sec were chosen so that bleaching was 
not significant. 





Fig. 2.2 Microscope and pathways of excitation and emission lights 
The model shows the configuration of the microscope setup. Yellow line, excitation light divided by a 
dichroic mirror from emission light (orange line) which is split into the donor channel and acceptor 
channel by another set of dichroic mirrors (image splitter).  
 
The experimental microscopic pictures were corrected for the background and for the 
inhomogeneous illumination according to the specific excitation wavelengths. The 
background image was acquired under the same settings as in the FRET experiments 
without excitation light. The inhomogeneous illumination was recorded by fluorescent slides 
(Chroma Technology, Rockingham, VT). Subpixel shifts between the donor and acceptor 
emission channel as result of imperfect alignment of the Dual View were corrected with the 
help of a reference grid structure. 
 
2.1.3 Data analysis, acquisition of the EfDA/γ value  
 
As mentioned above FRET appearance will increase in cAMP absence and decrease in 
presence of cAMP. If the FRET efficiency E is high, a strong acceptor emission will be 
apparent, whereas in case of FRET efficiency decrease the A emission will also diminish in 




favor of a stronger donor emission. Traditionally, the ratio between the emission intensities, 
deriving from D (mCerulean), and those deriving from A (mCitrine), was used as a FRET 
equivalent measure, whereas FRET is inversely proportional to the ratio. These FRET ratio 
measurements are usually done at a single excition wavelength, optimal for donor excitation. 
However, this measure cannot distinguish between FRET and non-FRET signals and is 
consequently unable to analyze absolute values of FRET or [cAMP], respectively. Hence, 
Hoppe et al. (Hoppe et al. 2002) developed a stoichiometric method that uses two excitation 
wavelengths and three filter sets to measure the FRET efficiency and the relative 
concentrations of donor and acceptor, as well as the fractions of donor and acceptor in 
complex. This method was further developed and applied on the Epac1 tandem construct 
CEPAC* in this department by Salonikidis et al. (Salonikidis et al. 2008). In the following, the 
term EfDA/γ, illustrating the FRET value, is used as response signal. fDA is the fraction of the 
total CEPAC* molecules which are in FRET state and γ is the ratio of the donor and acceptor 
extinction coefficients which is difficult to obtain and not necessary to analyze in this 
approach.  
The EfDA/γ value is calculated pixelwise (Eq. 1) using the fluorescence intensity F of the three 
different camera images (a, b and c) acquired during FRET measurements as described in 
chapter 2.1.2 Microscopy: 
a: , b: c:  ,  
with the indices: ex_λ_D:  at donor excitation wavelength; ex_λ_A: at acceptor excitation 
wavelength; em_λ_D: donor emission channel; em_λ_A: acceptor emission channel 
 
                                
(Eq. 1, According to Salonikidis et al. 2008)  
α =
 
 constitutes the relative acceptor fluorescence signal and was acquired in 






























































acceptor emission channel, often called bleedthrough and is also derived from separate 
donor and acceptor measurements.  All calculations were performed with MATLAB 
(MathWorks, Natick, MA) and the DIPimage Toolbox (image processing toolbox for Matlab, 
Delft University of Technology, Netherlands) using MATLAB scripts programmed by Guobin 
Bao.  
 
2.1.4 CEPAC* calibration  
 
 As pointed out earlier the EfDA/γ value is inversely proportional to [cAMP] and can be 




For this calibration of the [cAMP] sensitivity of CEPAC* the “sensitized emission” FRET 
signal was recorded in fluorescence spectrometry measurements by P. Salonikidis as 
described in Salonikidis 2011 (Salonikidis et al. 2011).  
The detected CEPAC* fluorescence signal  
)(iF
 at an excitation wavelength λi consists of 
a part of donor emission (here represented by 
)(refDF ) and a part of acceptor emission 
(here represented by )(
r e f
AF ). The fraction of each emission signal can be derived by fitting 
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() Di FDref () Ai FAref ()                                                               
(Eq. 2, According to Salonikidis et al. 2008)
 
 
 iD  and  iA  are the apparent D- and A concentrations which were used as fitting factors.  
Calibration was done for D excitation wavelength (i=1) and for A excitation wavelength (i=2). 
The D and A reference spectra must be obtained separately in cells containing only donor or 
only acceptor fluorophores.  
The apparent acceptor concentrations at D excitation [A1] and at A excitation [A2] were used 
to deduce the following term (Eq. 3) (See also Eq. 1).  
)]([/ cAMPfEfDA 






A1  A2 
 A2                                                                                   
(Eq. 3, According to Salonikidis et al. 2008)
 
 
Again, α constitutes the ratio of the relative acceptor emission intensities at both wavelengths 
applied.  
The [cAMP] dependence of EfDA/γ can be expressed by a Hill equation which describes the 
binding equilibrium of a ligand to a macromolecule in the presence of other ligands (Eq. 4).  
,                                     
 
(Eq. 4, According to Salonikidis et al. 2008) 
 
where nH is the Hill coefficient indicating the amount of cAMP binding places. p0 and pmax are 
offset and maximum amplitude parameters and EC50 is the [cAMP] when 50% of the cAMP 
binding sites are occupied. Again, EfDA/γ is inversely proportional to the cAMP concentration.  
With help of these calculations the measured EfDA/γ values can be converted into [cAMP] 
values.  
 
2.1.5 Excitation and emission spectra 
 
Optimal excitation and emission wavelengths have been determined in previous 



























Fig. 2.3 mCerulean and mCitrine emission spectra 
The image shows the respective emission spectra of mCerulean (blue line) with a peak at 475 nm and 
mCitrine (orange line) with a peak at 526 nm, recorded in fluorescence spectrometry measurements 
by P. Salonikidis in n=5 experiments. The second peak in the mCerulean curve (500 nm) is due to the 
raman effect which occurs in cuvette measurements and can be corrected in analysis protocols. Grey 
bars indicate the respective channels for donor (470/30 nm) or acceptor (535/30 nm).  
 
It is important to note that the chosen channel for donor emission (left grey bar in Fig. 2.3) 
does hardly contain any acceptor emission. In contrast it is not possible entirely to exclude 
donor emission in the emission light of the acceptor filter set (right grey bar in Fig. 2.3). This 
bleedthrough is corrected for each measurement. (See above)  
In order to detect and distinguish the two coexpressed receptor subtypes on a single cell 
level under the microscope, 5-HT7 receptors were tagged with the N-terminal fluorescent 
protein mCherry (Promega). Prior to FRET measurements 5-HT7 expression was confirmed 
through fluorescence identification using a red light filter at excitation wavelength of 580 nm 
and emission detection at 620 nm. Figure 2.4 shows the mCherry emission spectrum.  





Fig. 2.4 mCherry and quantum dot emission spectra 
The image depicts the emission spectra of mCherry (dark red) with a peak at 606 nm and quantum 
dots (green) with a peak at 650 nm, recorded in fluorescence spectrometry measurements. mCherry 
and mCerulean emission spectra are shown as in Fig. 2.3. Black line 1 indicates mCherry filter (620 
nm), black line 2 indicates QD filter (655 nm).  
 
5-HT1A receptors however were labeled with quantum dots (QD) (Invitrogen) recognizing 
antibodies against HA tags of recombinantly expressed 5-HT1A receptors. Pictures were 
taken prior to FRET experiments to ensure 5-HT1A expression. Quantum dots were recorded 
with a QD filter set at 655nm (Fig. 2.4). Fig. 2.4 also reveals that mCherry and also QD 
emission does not appear in the donor or acceptor channel.  
In control experiments with non-tagged receptors, we verified that neither the N-terminal 
fluorescent tags nor QD labeling affected agonist affinity or signal transduction.  
Figure 2.5 shows the development of donor and acceptor emission upon increasing [cAMP] 
indicated by the gray arrows. The higher [cAMP] rises, the bigger is the contribution of donor 
emission and the lower the contribution of acceptor emission to the biosensor emission 
signal at 420 nm excitation (see Eq. 1). The curve shapes of donor and acceptor reference 
spectra were obtained by separate measurements. All presented spectra are corrected for 
background and autofluorescence (Salonikidis et al. 2011). 
 





Figure 2.5 [cAMP] dependent donor and acceptor emission in CEPAC* 
 From Salonikidis et al. (2011. P. 23423) [cAMP] dependent CEPAC* emission spectrum. Spectra 
were obtained from a diluted supernatant of homogenized and centrifuged CEPAC*. cAMP was 
directly applied into the supernatant solution. CEPAC* emission spectra were unmixed into linear 
fractions of mCerulean and mCitrine reference spectra. Curve shapes of these reference spectra were 
obtained by separate measurements.  
 
2.2 Cell culture and transfection  
 
 Mouse N1E-115 neuroblastoma cells from the American Type Culture collection (LGC 
PROMOCHEM, Wesel, Germany) were cultered in DULBECCO´S MODIFIED EAGLE´S MEDIUM 
(SIGMA-ALDRICH, Munich, Germany) containing 10% fetal calf serum (FCS) and 1% of a mix 
of penicillin and streptomycin at 37°C under 5% CO2. Twenty-four hours before transient 
transfection, the neuroblastoma cells were seeded at low-density (1x106 cells) in 10 mm 
dishes including glass covers slips on the bottom (for microscopic measurements). The cells 
were transfected with appropriate vectors using LIPOFECTAMINE2000 reagent (INVITROGEN) 
according to the manufacturer’s instruction. The transfected cDNA was encoding for 
following proteins: (a) mCerulean monomeric cyan fluorescence protein (pECFP-N1, 
CLONTECH LABORATORIES, Mountain View, CA, USA), (b) mCitrine monomeric yellow 
fluorescence protein (pEYFP-N1, CLONTECH LABORATORIES), (c) the CEPAC* construct 
mCitrine–Epac(∆DEP-CD)–mCerulean in a pCDNA3 from Ponsioen et al. (Ponsioen et al. 
2004),  (d) mCherry (Promega), or (e,f,g,h) a cotransfection of either the HA-
/pTargetmCherry-tagged 5-HT1A receptor or/and the myc-/pTargetmCherry-tagged 5-HT7 
receptor cloned into the pcDNA3.1 plasmid together with CEPAC*. Cells for experiments on 
the G Protein level were additionally transfected with cDNA encoding for following proteins: 
(i) Dominant inactive Gi alpha subunit (Giα 3 Q 202T d/n), or (j) permanent active Gs alpha 




subunit (Gsα Q227C). Three hours after transfection, cells were serum starved over night 
before analysis. Continuative incubation led to an aggregation of the CEPAC*-proteins.  
 
2.2.1 Treatment with pertussis toxin 
 
Pertussis toxin (PT) inhibits the Gi alpha subunit of G proteins through ADP-ribosylation. PT 
was used to determine which G protein pathway is preferred in 5-HT1A and 5-HT7 receptor 
coexpressing cells. Transfected N1E-115 cells were incubated with PT for 16 hours prior to 
analysis, at a concentration of 0.1  g/ml diluted in standard culture medium (Griffin et al. 
2007). 
 
2.2.2 Quantum dot staining 
 
As part of receptor expression analysis 5-HT1A receptors were detected in living cells through 
labeling with quantum dots. As there are no anti-5-HT receptor antibodies available that 
recognize extracellular loops of 5-HT receptors, antibodies directed against HA- and myc-
tags (Santa Cruz) of recombinantly expressed 5-HT receptors were used to couple quantum 
dots to the surface of the cells. Cells were incubated with 1ng of primary antibody diluted in 
OptiMEM for 5min and were extensivly washed with OptiMEM before addition of 1nM QD-
Fab conjugates (Invitrogen) in QptiMEM for 5min. QDs were removed by extensive washing 
over a period of 10min.  
 
2.3 Solutions, agonists and antagonists  
 
During experiments cells were kept in tyrode solution (table 2.1). For preparation the listed 
chemicals were diluted in appropriate amount of distilled water. Afterwards solution was 















in mM   
150 5 2 1 10 10 100 
 
Table 2.1, Content tyrode solution, pH7.4, osmolarity 340 mOsm. 
 
Forskolin is a known AC activator and therefore raises the level of intracellular cAMP 
(Takeda et al. 1983). A Forskolin concentration of 100 nM in bathing solution was chosen in 
order to ensure a mean cellular cAMP level, which allows the cAMP concentration to 
decrease or to increase after 5-HT-stimulation. 100nM is according to the EC50 value (98 ± 
45 nM) of Forskolin, which was previously determined from colleagues (Guobin Bao, data not 
published) in separate experiments (n = 86 cells) for our cell model, using EfDA/γ as a 
response signal. Before measurements, cells were incubated for about 10 min in Forskolin 
(Fluka; 47735, EC No. 2664109). Selective agonists and antagonists in 5-HT1A, 5-HT7 
coexpression experiments had to be applied in concentrations high enough to excite or 
inhibit the particular preferential receptor but low enough to not affect the other respective 
receptor. In control experiments with single receptor expression the same concentrations of 
agonists and antagonists were used to guarantee same conditions. Serotonin (Sigma-
Aldrich) was supposed to activate both receptors and was given in a concentration of 1 µM 
(Andressen et al. 2006, Sharif et al. 2004). Alternatively, 5-HT1A stimulation was realized by 
application of 1µM 8-OH-DPAT (TOCRIS BIOSCIENCE, Bristol, UK) and 5-HT7 stimulation was 
mediated by application of 1 µM 5-Carboxamidotryptamine (1 µM 5-CT, TOCRIS BIOSCIENCE, 
Bristol, UK), or 100nM  AS19 ((2S)-(+)-5-(1,3,5-Trimethylpyrazol-4-yl)-2-(dimethylami 
no)tetralin) (TOCRIS BIOSCIENCE, Bristol, UK). AS19 is a selective 5-HT7 agonist with only 
moderate affinity for 5-HT1A. The Ki values, displaying the affinity of the agonists (Cer et al. 
2009) are 4.6 nM for 5-HT7 and 110 nM for 5-HT1A (Bosker et al. 2009). The reason that 
AS19 was given in a slightly higher concentration than the Ki values would suggest may be 
due to dilution effects in the experimental chamber at these very low concentrations. Control 
measurements excluded an affect of 100 nM AS19 on 5-HT1A receptors in the conducted 
experiments (Fig. 3.10). In order to block receptor stimulation the potent and selective 5-HT7 
receptor antagonist SB-269970-A (Sigma-Aldrich) (Lovell et al. 2000, Hagan et al. 2000) had 




been applied at a concentration about 1 µM. The corresponding Ki values are 1.26 nM for 5-
HT7 and over 1 µM for 5-HT1A according to the manufacturer. The potent, selective and silent 
5-HT1A receptor antagonist WAY-100635 (Tocris) (Fletcher et al. 1996) was used at 1 µM to 
inhibit 5-HT1A.  Pharmacological profiling by Chemel et al revealed Ki values of 2.2 nM and > 
10,000 nM for 5-HT1A and 5-HT7, respectively (Chemel et al. 2006). Control experiments 
confirmed selectivity of used agonists and agonists in all further experiments.  
 
2.4 Widefield fluorescence microscopy 
 
2.4.1 Experimental setup 
 
The measuring setup for microscopy and fluorescence excitation is placed on a vibration-
cushioned desk and surrounded by a Faraday cage. (Fig. 2.6) Underneath the objective of 
the upright microscope that is configured as pointed out above is the bathing chamber 
located on the object table. (Fig. 2.7)  The chamber is embedded in a Plexiglas plate. The 
bottom is build of a picture frame glass (30mm Ø, thickness 0,13mm) which is attached to 
the bottom side of the Plexiglas with Vaseline. The chamber has a total volume of ca 500 µl.  
It is equipped with a solution inflow through plastic tubes connected to elevated containers. 
The speed of inflow could be adjusted through a drip system. A valve system allowed the 
choice of the desired solution. The solution was sucked out of the bath chamber with a 
flexible-tube pump. The inflow was adjusted on 1 drop per second and the suction 
accordingly to ensure a smooth solution exchange. The different solutions could therefore be 
applied rapidly to the imaging chamber to quickly reach the final concentrations indicated 
above. The object table can be moved freely underneath the objectives.  
 





Fig. 2.6 Microscope setup 
From Biophysikalisches Praktikum (Salonikidis 2003) The picture shows the experimental setup. 1, 
upright microscope; 2, vibration-cushioned desk; 3, Faraday cage; 4, object table; 5, patch-clamp 
electrode; 6, valve system.  
 
 
Fig. 2.7 Bathing chamber 
From Biophysikalisches Praktikum (Salonikidis 2003) The picture shows the measuring chamber with 
solution inflow (1), solution suction (2) and electrode (3).  
 
The specimen can be observed either through the ocular or live on the pc monitor using the 
IXON camera DV887DCS (ANDOR TECHNOLOGY, South Windsor, CT, USA) where the 
measurements are recorded. During the experiments all light is switched off and the setup is 
protected from remaining light using a cloth blanket all around the cage.  
 




2.4.2 Experimental procedure 
 
For the measurements, the coverslips carrying the transfected N1E-115 cells were taken out 
of the cell culture dishes with a pincette and positioned into the chamber. The chamber was 
filled with tyrode containing the additives as indicated above. The images taken are recorded 
by the camera corresponding pc program AndorIQ (Andor Technology) with the three distinct 
images as explained above. The horizontal readout was adjusted at 5,000 MHz and the 
vertical readout at 3,400 MHz. Before FRET measurements cells were measured that 
express just the fluorescent dyes for calibration purpose with the same filter sets as in FRET 
trials. For these control measurements the cells were recorded for 120 seconds. For receptor 
expression analysis the filter sets were manually changed according to the respective 
staining. Pictures were taken with a red filter set for detection of mCherry tagged 5-HT7 and a 
QD filter was used for recording of QD labeled 5-HT1A receptors. After expression analysis-
image-taking the picture frame has not been shifted again, so that FRET measurements 
were performed with cells expressing both sorts of receptors. In subsequent analysis only 
these cells have been evaluated that expressed both receptors. In the actual FRET 
measurements the fluorescence was monitored over three periods of time, 90 s before, 360 s 
during agonist application, 420 s during simultaneous application of agonist and potential 
antagonist (Exemplary time table and measurement see 3.2). For selection of different 
solutions during the experiment the afferent tubes were opened and closed manually with 
valves. For pertussis toxin experiments and experiments with cells expressing dominant 
inactive Gi proteins the same time scale and application was used.  
After data acquisition the IQ-program created a two color series. From each image one half-
image was overlapped with the other half-image. The two colors of the series represented 
the emission light of the two channels of the image splitter. An area of interest was defined 
around the cell and from the mean intensity of this area, and the background intensity was 
subtracted by defining another area of interest in the background. Final data analysis was 






3 Results  
 
3.1 Expression analysis and receptor ratio in living cells 
 
The purpose of the thesis is to investigate the impact of 5-HT1A-5-HT7 receptor coexpression 
on signaling with [cAMP] as preliminary endpoint. In order to be able to establish a statement 
about the two-receptor interaction it is essential to ensure a proportionally equal expression 
level of both receptor subtypes in the examined cells. Both applied expression-plasmids were 
of the same size and cloned into the same vector with the same promoter. Therefore it can 
be expected that the two receptors are expressed in equal shares when the cells are 
transfected with the same amount of cDNA. In order to prove that this protocol results in 
equal expression levels, three steps of confirmation were implemented; FACS analysis 
should validate the expression of the two receptors in an average batch of transfected cells, 
functional analysis using antagonists and optical verification in each measuring cell further 
verified equal expression levels. For FACS analysis N1E-cells were transfected with the 
same amount of cDNA encoding for the 5-HT7 receptor as with cDNA encoding for the 5-
HT1A receptor. This experiment was performed by Dr. Marcus Niebert. FACS (Fluorescence-
activated cell sorting) analysis can provide information about the properties of single cells 
when the separately pass a laser beam in an annular fluid stream. It can therefore be used to 
detect cell surface components such as receptors by attaching to these specific antibodies 
conjugated with fluorochromes which are optimally excited at the wavelength emitted by the 
laser. A photomultiplier (PTM) detects the fluorescent intensity emitted by the passing cells. 
The intensity is proportional to the number of fluorescent markers and consequently 
receptors on each cell.  In this case N1E cells expressing 5-HT1A and subsequently cells 
expressing 5-HT7 receptors were measured. The receptors were tagged with antibodies (HA 
for 5-HT1A and myc for 5-HT7) conjugated with fluorescent quantum dots (wavelength: 655 
nm). Since the receptors were labeled with the same fluorescent marker they were measured 
consecutively to avoid signal disturbance. The data was plotted in a single parameter 
histogram with a logarithmic scale of the fluorescent intensity on the x-axis and the cell count 
on the y-axis. Fig. 3.1 depicts that two cell populations of the same size, one expressing 5-
HT1A (red), the other one expressing 5-HT7 (grey) reveal an equal fluorescent intensity 
pattern. The two populations show virtually no difference of cell surface labeling. Therefore, 
one can infer that the cells express the same amount of 5-HT1A receptors as 5-HT7 receptors 
when the same amount of cDNA has been transfected. The intensity peak lies at 





amplify the signal. The voltage is usually chosen so that non fluorescent cells or particles lie 
within the first decade of the fluorescent scale (special thanks to Dr. Marcus Niebert). 
 
Fig. 3.1 5-HT1A and 5-HT7 expression on N1E cells 
The picture shows an overlay FACS histogram of the fluorescence patterns of two populations of N1E 
cells. Measurements have been conducted by Dr. Marcus Niebert. One population has been 
transfected with cDNA for 5-HT1A receptors (red) and the other one has been transfected with the 
same amount of cDNA, coding for 5-HT7 receptors (grey). The fluorescent patterns of the HA-tagged 
5-HT1A cells and the myc-tagged 5-HT7 expressing cells, both marked with fluorescent quantum dots 
(Invitrogen, 655 nm), show virtually no difference. Therefore an equal expression level of the two 
serotonin receptors can be inferred. The intensity peak lies at 10
4
 and is directly correlated to the 
voltage applied to the recording PTM detector.  
 
The FACS data already gave an estimation about the expression level of an averaged batch 
of cells. However, the expression ratio in single cells can vary significantly. In order to select 
single cells with appropriate receptor ratio in the actual measurements, optical verification of 
the expression was performed in each experiment and for every measuring cell.  
To distinguish the two receptor subtypes on a single cell level under the microscope, 5-HT7 
receptors were tagged with the N-terminal fluorescent protein mCherry, whereas 5-HT1A 
receptors were labeled with quantum dots (QD) recognizing antibodies against HA tags of 
recombinantly expressed 5-HT1A receptors. The combination of one transfected marker 





chosen for two reasons. The first reason was to avoid transfection of too much alien cDNA 
and therefore potentially alter protein expression rates and the second reason was to 
coordinate the multiple fluorochromes (mCeruean, mCitrine, mCherry, QD) without 
unintended overlap of their spectra (see 2.1.5). Control experiments were carried out to 
assure that neither N-terminal fluorescent tags nor QD labeling affected 5-HT signaling. 
These controls revealed that mCherry tagging of 5-HT1A receptors resulted in blunted 
signals, whereas 5-HT7 receptors were not affected by mCherry tags (Fig. 3.8). The diagram 
shows that QD labeling in turn did not impair 5-HT1A receptor signaling. For subsequent 
experiments only these cells should be selected and analyzed which expressed both 
receptors in equal amounts. Therefore two fluorescence emission pictures of each sample 
were taken prior to all 5-HT measurements. One picture with a red light filter at 580 nm 
excitation to indentify mCherry tagged 5-HT7 receptors and a second picture with a QD filter 
set at 655 nm to detect the QD labeled 5-HT1A receptors (see also 2.1.5). Fig. 3.2 shows how 
measuring cells have been selected. Only if a certain cell was clearly visible in both channels 







Fig. 3.2 5-HT1A- 5-HT7 expression analysis on measuring cells 
A-C, The images show the same field of view and the same batch of N1E-cells at different excitation 
wavelengths and different emission filter sets. The population of cells coexpressed 5-HT1A and 5-HT7 
receptors which are marked with QD and mCherry fluorochromes, respectively.  A: red light filter, 
showing the mCherry fluorescence of 5-HT7 receptors at 580 nm excitation, B: QD filter, showing 
quantum dots attached to 5-HT1A receptors at 655 nm excitation, C: transmitted light, no filter. Red 
circles indicate a coexpressing cell which was subsequently taken for measurements.  
D, Overlap of two pictures of the same 5-HT1A- 5-HT7 coexpressing cells at different excitation and 
emission filters. The image is derived from one picture showing the distribution of QD labeled 5-HT1A 
receptors in green color and a second picture displaying the presence of mCherry tagged 5-HT7 





indicated in A-C. White arrows refer to cells, which expressed both receptors and were taken for 
analysis.  
 
This analysis is not quantitative but it is able to prove coexpression in single cells. In addition 
to this optical confirmation, functional behavior strongly suggests the significant presence of 
both receptors in single cells, as demonstrated in Fig. 3.3. The figure depicts the 
fluorescence intensity curves of the CEPAC* sensor in 5-HT1A - 5-HT7 coexpressing cells.   
In this measurement 5-HT receptors were activated with 1 µM serotonin and subsequently 
blocked with the 5-HT7 specific antagonist SB-269970 hydrochloride (SB) (Hagan et al. 
2000). In similar experiments the receptor activation was significantly blocked with WAY 
100635 (WAY), a specific 5-HT1A receptor antagonist (Chemel et al. 2006) (all data shown 
below). Both antagonists were applied at a concentration of 1 µM. Control experiments with 
only 5-HT7 expressing and only 5-HT1A expressing cells excluded that antagonists at this 
concentration had a comparable influence on the nonspecific contrary receptor (Fig. 3.7). 
The two antagonists were therefore both able to inhibit receptor activation of 5-HT1A and 5-
HT7 coexpressing cells, suggesting that either of the receptors were expressed in a 
functional effective quantity. This is under the assumption that coexpression does not change 
receptor function or antagonist specificity. Nevertheless, the fact, that coexpressing cells 
show altered activation- and inhibition patterns compared to single receptor expressing cells, 
is by itself a proof for the presence of both receptor subtypes in a functional significant 






Fig. 3.3 Functional coexpression verification 
Intensity curves of the CEPAC*-sensor linked fluorophores mCitrine and mCerulean over time in the 
IQ acquisition program. A, mCitrine + mCerulean emission at 420 nm excitation; B, mCitrine emission 
at 500 nm excitation; C, fluorescent coexpressing cells during exciation, blue circle indicates 
measuring cell (as seen in Fig. 3.2). Picture A shows the intensity at donor excitation whereas picture 
B follows the intensity at direct acceptor excitation and serves as control. Again, excitation at acceptor 
wavelength does not result in FRET. Upon agonist application (yellow bar) a change in acceptor 
emission intensity becomes apparent in picture A. This implies a change of FRET and consequently a 
change of [cAMP]. Direct acceptor excitation (B) does not show this change.  Green bar, SB-269970 
inhibition.  
 
3.2 cAMP concentration measurements 
 
The FRET-based fluorescence measurements were performed (as described in 2.4.2) on 
N1E-115 neuroblastoma cells, co-transfected with plasmids encoding for CEPAC* and either 
for serotonin receptor subtype 5HT7 or 5HT1A, as well as on cells coexpressing both 
receptors. Cells in subsequent experiments were incubated in 100 nM Forskolin before 
(about 10 min) and also during measurements so as to approximate an average cAMP level, 
which allows the two-receptor model both, to increase and to decrease [cAMP]. 100 nM is 





experiments (n = 86 cells) for our cell model, using EfDA/γ as a response signal by my 
colleagues G. Bao and P. Salonikidis. In each measurement the fluorescence was monitored 
over three periods of time, 90 s before, 360 s during agonist application, 420 s during 
simultaneous application of agonist and respective antagonist. Fig. 3.4 illustrates exemplary 
time lapses of EfDA/γ recordings of cells coexpressing 5-HT1A and 5-HT7 receptors.  
 
A       (T1) (T2)  
     
 
 






Fig. 3.4 [cAMP] progression upon serotonin application and inhibition  
N1E cells were co-transfected with CEPAC*, 5-HT1A and 5-HT7 receptors. Cells were pre-incubated in 
100 nM Forskolin (EC50 value of adenylate cyclase-activation). Application of 1µM serotonin led to 
increase of FRET intensity (EfDA/γ) which corresponds to a cAMP decrease. Application of the 5-HT7 





















specific antagonist SB-269970 inhibits the effect. A shows two EfDA/γ-pictures of cells at different time 
points, including 12 regions of interest per picture (white). AT1 represents a registration before 
serotonin application and AT2 during serotonin application. The EfDA/γ values are translated into a 
color code. B, the displayed Δ(EfDA/γ) time lapse (black line) consist of averaged values of 12 regions 
of interests (ROI). The error SE is displayed as a gray dashed line.  
 
3.2.1 Kinetic measurements, comparison of stimulation – response intervals  
 
Fig. 3.5 reveals the delays between effector application and EfDA/γ changes depending on 
the volume of the bathing chamber and the fluorescence sensor.  
Picture A shows the intervals (in sec) between agonist application and detectable effect of 
the different receptors in a setup with a solution chamber of about 1.5 ml. Depending on the 
sensor, the times differed from 37 ± 7 s with the former sensor (EPAC) (see 3.4) and 37 ± 1 s 
with the new sensor (CEPAC*) for the 5-HT7 receptor to 62 ± 11 s (EPAC) and 16 ± 1 s 
(CEPAC*) for 5-HT1A. In this case the new sensor CEPAC* appeared more reliable in terms 
of the reproducibility of the intervals. However, there was the paradoxical situation that 
depending on the sensor 5-HT1A exhibited longer or shorter intervals than 5-HT7. Therefore 
the bath chamber was optimized and reduced to a total volume of about 500 µl and only the 
new sensor has been utilized in subsequent experiments. Fig. 3.5 B consequently shows the 
intervals between agonist application and EfDA/γ change in the smaller chamber with the 
CEPAC* sensor. The times averaged 9 ± 1 s for 5-HT7 and 9.5 ± 1 s for 5-HT1A and 
displayed no detectable difference among the used chemicals. These delays can be 








Fig. 3.5 Kinetics of [cAMP] changes depending on the experimental setup and sensor 
The figure reveals the intervals between agonist application and EfDA/γ change in 5-HT experiments as 
indicated in Fig. 3.4. (error bars, SE) A, bigger bath chamber (1.5 ml) for the former sensor EPAC and 
the new sensor CEPAC* (10 ROIs each); B, optimized chamber (500 µl) with CPEAC* only (10 ROIs 
each).  
 
The following block diagrams in 3.2.2 were all derived from average EfDA/γ values at stable 







































3.2.2 5-HT activation of 5-HT7 and 5-HT1A coexpressing cells  
 
Prior to 5-HT application the intracellular cAMP concentrations were analyzed. This step was 
important to exclude that up or down regulation of AC by basal receptor activity would 
regulate the cAMP level beyond the dynamic range of the biosensor before 5-HT application. 
Therefore, the biosensor was calibrated in order to assign quantitative cAMP concentration 
values to the measured EfDA/γ values as described previously (Salonikidis et al. 2008). In all 
cases the cAMP concentrations were within the dynamic range of the biosensor. 
Fig. 3.6 reveals the EfDA/γ changes upon agonist application for 5-HT7 and 5-HT1A receptors 
separately and coexpressed in the same cells. First, 5-HT7 expressing cells were stimulated 
with serotonin at a concentration of 1 µM. Fig 3.6 shows that 5-HT application led to a 
decrease of EfDA/γ of about 0.35 ± 0.03 (EC50 value derived from Andressen et al. 2006) in 
cells with this receptor type. A decrease of EfDA/γ corresponds to an increase of intracellular 
[cAMP], which was expected since the 5-HT7 receptor is described to enhance AC activity via 
Gαs. Specific 5-HT7 receptor blockade with 1µM SB inhibited the agonist induced rise about 
70 ± 6 % (Fig. 3.7 A). That correlates to an EfDA/γ increase of about 0.18 ± 0.06. SB in this 
concentration was hardly able to block receptor activation of cells expressing only the 5-HT1A 
receptor in subsequent measurements (3 ± 1 %; ΔEfDA/γ 0.03 ± 0.01) (Fig. 3.7 B). These 
values represent the blocking abilities of SB for the respective receptors and correspond to 
SB receptor affinities in literature: pKI 8.9 ± 0.1 for 5-HT7 and < 6.0 for 5-HT1A (Hagan et al. 
2000). 
Afterwards, 5-HT1A expressing cells were stimulated with 1µM 5-HT. Fig. 3.6 shows an 
increase of the biosensor signal EfDA/γ of about 0.42 ± 0.02 upon 5-HT application (EC50 
value derived from Sharif et al. 2004). This increase corresponds to a decrease of [cAMP] 
and was expected since the 5-HT1A receptor is described to inhibit AC activity via Gαi. This 
effect was blocked to 77 ± 7 % by 1µM specific 5-HT1A receptor antagonist WAY (Fig. 3.7 B). 
In contrast single 5-HT7 receptor activation in absence of 5-HT1A was only blocked about 25 
± 14 % by the same concentration of WAY (EfDA/γ change of 0.042 ± 0.03) (Fig. 3.7 A). 
These blocking values are also in accordance to literature WAY pKI values of 8.66 and < 5.0 
for 5-HT1A and 5-HT7, respectively (Chemel et al. 2006). 
Eventually, 5-HT7 - and 5-HT1A coexpressing cells were stimulated with 1 µM serotonin. This 
activation led to an increase of EfDA/γ about 0.46 ± 0.04 (Fig. 3.6) which correlates to a 
decrease in [cAMP]. This is virtually the same effect as in cells which express only 5-HT1A. It 





5-HT7 but appeared clearly dominant. It is also noteworthy, that 5-HT1A and 5-HT7 receptor 
coexpression seemed to cause a slightly stronger change in FRET and displayed enhanced 
inhibition (see below) compared to cells which express only one receptor subtype. An 
unpaired t test with Welch´s correction revealed that the EfDA/γ change in 5-HT7 – only 
expressing cells differs significantly from the change in coexpressing cells with a p-value of 
0.035 in a 95% confidence interval, whereas the EfDA/γ values of 5-HT1A – only expressing 
cells and coexpressing cells turned out to not differ significantly.  
 
Fig. 3.6 Changes of cAMP concentrations upon 5-HT activation 
The figure depicts the changes of EfDA/γ after application of 1 µM serotonin on cells that express either 
5-HT1A, 5-HT7 or both receptors at the same time. Experimental setup as described in 3.2. Error bars, 
SE. 5-HT1A expressing cells exhibited a rise about 0.42 ± 0.02 (n = 126 cells/ROIs), 5-HT7 expressing 
cells showed a descent about 0.35 ± 0.03 (n = 213 cells/ROIs) and coexpressing cells exhibited an 








Fig. 3.7 Specific blockade of previous 5-HT activation in single receptor expressing cells  
Blocking abilities of the 5-HT7 specific antagonist SB and the 5-HT1A specific antagonist WAY after 
previous serotonin activation, in percent. Experimental setup as described in 3.2. Error bars, SE. A, 5-
HT7 expressing cells were blocked by SB to 70 ± 6 % (n = 57 cells/ROIs) and by WAY to 25 ± 14 % (n 
= 21 cells/ROIs); B, 5-HT1A expressing cells were blocked by SB to 3 ± 1 % (n=52 cells/ROIs) and by 






3.2.3 How receptor labeling affects signaling 
 
Fig. 3.8 A and B reveal control experiments in single receptor expressing cells. In order to 
identify 5-HT1A and 5-HT7 on the measuring cells, the receptors have been labeled as 
described previously in 3.1. Ideally, receptor labeling should not interfere with the actual 
FRET measurements. Fig. 3.8 A shows the EfDA/γ changes upon application of 1 µM 
serotonin in 5-HT1A expressing cells, tagged with the transfected fluorophore mCherry or the 
antibody conjugated quantum dots compared to unlabeled controls. The mCherry tagged 
samples delivered weaker results (EfDA/γ change: 0.28 ± 0.03) than QD labeled cells (0.4 ± 
0.02) (controls: 0.41 ± 0.03). FRET results of 5-HT7 expressing cells by contrast were not 
significantly affected by mCherry tags. (Fig. 3.8 B) Thus, it became apparent that 5-HT7 
receptors labeled with mCherry and 5-HT1A receptors tagged with QDs were the best 







































Fig. 3.8 Control measurements: How receptor labeling affects FRET signals 
EfDA/γ changes upon stimulation with 1 µM 5-HT. Experimental setup as described in 3.2. Error bars, 
SE. EfDA/γ reaction is inversely proportional to [cAMP] development. A, 5-HT1A expressing cells without 
tag (0.41 ± 0.03, n = 27 cells/ROIs), mCherry tag (0.28 ± 0.03, n = 21) or QD labeling (0.4 ± 0.02, n = 
8). QD labeling yielded stronger results than mCherry tagged cells. B, 5-HT7 expressing cells were not 
significantly influenced by mCherry tags (-0.34 ± 0.03, n = 15 cells/ROIs; controls: -0.36 ± 0.04, n = 
74)  
 
3.2.4 Functional interaction between 5-HT1A and 5-HT7 receptors 
 
Since GPCRs generally may form homo- or hetero-oligomers (Maggio et al. 2005, Gurevich 
and Gurevich 2008, Woehler and Ponimaskin 2009, Renner et al. 2012) which sometimes 
results in altered signaling properties, we were interested in the functional interaction 
between the two contrary acting receptors 5-HT1A and 5-HT7 when they are expressed in the 
same cells. The goal was to characterize the functional state of a putative 5-HT1A-5-HT7 
receptor hetero-oligomer. Therefore, the functionality of the agonist and antagonist binding-
sites of both receptors should be investigated in coexpressing cells. Stimulation of these cells 
with 1 µM 5-HT increased EfDA/γ about 0.46 ± 0.04 (Fig. 3.6). In the following, this rise was 
blocked with 1 µM of the 5-HT1A receptor specific antagonist WAY to 92 ± 7 % (Fig. 3.9), 





receptor specific antagonist SB also inhibited the previous EfDA/γ increase about 75 ± 4 %. 
The response to SB indicates accessible and functional 5-HT7 receptor binding-sites. It is 
again notable, that in coexpressing cells 1 µM SB exhibits even stronger blocking abilities 




Fig. 3.9 Specific inhibition of serotonin activation in 5-HT1A – 5-HT7 coexpressing cells 
Blocking of previously 5-HT - induced EfDA/γ rise in coexpressing cells with the 5-HT7 specific 
antagonist SB and the 5-HT1A specific WAY in percent. Experimental setup as described in 3.2. Error 
bars, SE. SB inhibits the rise about 75 ± 4 % (n = 114 cells/ROIs) and Way even blocks the effect 
about 92 ± 7 % (n = 27).  
 
In the coexpression experiments seen so far, the 5-HT1A pathway appeared dominant and it 
was possible to block this effect with the 5-HT7 specific antagonist SB. Hereinafter, 
coexpressing cells were stimulated with the 5-HT7 specific agonist AS19 to see if specific 5-
HT7 activation is able to evoke the same results. AS19 displays high affinity for 5-HT7 and 
only moderate affinity for 5-HT1A receptors (Bosker et al. 2009). So as not to coactivate 5-
HT1A receptors, AS19 was applied at a concentration of 100 nM. Fig. 3.10 A reveals that 
AS19 in this low concentration had virtually no effect on 5-HT1A – only expressing cells 





(-0.13 ± 0.04). In coexpressing cells instead, AS19 induced a strong response. 100 nM AS19 
led to a 5-HT1A – like [cAMP] decrease.  The EfDA/γ value was increased about 0.45 ± 0.06, 
suggesting accessible and functional 5-HT7 receptor binding-sites. A boost of the signal due 
to potential hetero-oligomerization is discussed in 4.1.1 Simultaneous application of specific 
antagonists in order to intensify the agonist specificity would disturb the interaction of 5-HT1A 
and 5-HT7 in an uncontrolled way. Therefore, the antagonist was applied separately, using 
the same protocol as described in 3.2. 1 µM 5-HT7 specific SB subsequently blocked the 
EfDA/γ rise about 90 ± 7 % in coexpressing cells. (Fig. 3.10 B) In 5-HT7 – only cells, the 
inhibition was only about 22 ± 5 %. The weak blocking ability in 5-HT7 – only expressing cells 
might be due to an overall weak response at this very low agonist concentration. However, 
even if only very few receptors are occupied with AS19, receptor binding might be very 








Fig. 3.10 Specific 5-HT7 stimulation and subsequent inhibition in coexpressing cells 
A, EfDA/γ changes after application of 100 nM 5-HT7 specific AS19 on cells that express either 5-HT1A, 
5-HT7 or both receptors at the same time. Experimental setup as described in 3.2.  Error bars, SE. 5-
HT1A expressing cells hardly showed an effect (0.04 ± 0.04, n = 11 cells/ROIs), 5-HT7 expressing cells 
showed a moderate response (-0.13 ± 0.04, n = 15 cells/ROIs) and coexpressing cells exhibited an 
increase about 0.45 ± 0.06 (n = 39 cells/ROIs). EfDA/γ reaction is inversely proportional to [cAMP] 
development. B, Inhibition of the AS19 induced effect with 5-HT7 specific SB in cells that express only 
5-HT7 (22 ± 5 %, n = 15) or coexpress 5-HT7 and 5-HT1A (90 ± 7 %, n = 39) 
 
3.3 G-Protein interaction 
 
 In order to track the signal transmission further downstream, the signaling cascade should 
be investigated on the G protein level. To determine by which G protein receptor stimulation 
of a putative 5-HT1A - 5-HT7 hetero-oligomer is mediated cells were incubated overnight in 0.1 
µg/ml pertussis toxin, a known inhibitor of Gi. Again, 5-HT1A receptors, when expressed 
alone, usually inhibit AC via Gi whereas 5-HT7 receptors activate AC via Gs. After pertussis 
treatment coexpressing cells exhibited no EfDA/γ response to 1 µM 5-HT (∆EfDA/γ = +0.02 ± 
0.01) (Fig. 3.11), which signifies the dominance of the Gi pathway in case of 5-HT1A - 5-HT7 
receptor coexpression. Additional measurements using a dominant inactive mutant of Gi, 
transfected in advance, confirmed these findings. Co-transfection of the Gi mutant diminished 





coexpressing cells (Fig. 3.11). The remaining EfDA/γ change can most probably be attributed 
to activity of endogenous Gi proteins.  
 
 
Fig. 3.11 [cAMP] changes at Gi protein block 
EfDA/γ change after stimulation with 1 µM 5-HT in 5-HT1A - 5-HT7 coexpressing cells. Experimental 
setup as described in 3.2. Error bars, SE. EfDA/γ reaction is inversely proportional to [cAMP] 
development. Previous transfection of a dominant inactive Gi protein mutant diminishes the effect to 
one third of the control value. Control: 0.46 ± 0.04 (n = 36 cells/ROIs), G i
 
mutant: 0.18 ± 0.06 (n = 40).  
Pretreatment with pertussis toxin (0.1 µg/ml overnight), a known Gi inhibitor almost totally blocks the 
activation. (0.02 ± 0.01, n = 38) 
 
3.4 Biosensor efficiency  
 
In early experiments the formerly used biosensor EPAC was utilized. In contrast to the newly 
developped CEPAC* construct, the older EPAC sensor carries the FRET pair CFP/YFP 
instead of mCerulaen and mCitrine. In many respects the new biosensor appears to be 





FRET efficiency response and a prolonged time window for stable experiments (Salonikidis 
et al. 2011). These results could be supported by comparing the fraction of reacting cells 
after transfection of either the old or the new sensor (Fig. 3.12). In FRET measurements not 
all transfected cells regularly reacted to receptor activation. CEPAC* transfected cells 
revealed a success rate of 89 ± 9 % compared to only 33 ± 7 % in measurements with EPAC 
transfected cells. The Figure shows data of FRET measurements in 5-HT1A receptor 
expressing cells which were either transfected with the older EPAC sensor or the new 
CEPAC* in 7 and 8 different preparations, respectively. The results were published in 
Salonikidis 2011 (Salonikidis et al. 2011). The new construct helped to make the experiments 
more constant and the here presented results more reliable. It increased the number of 
measuring cells and therefore the significance of the data. 
 
 
Fig. 3.12 Sensor dependant fraction of reacting cells  
 
The figure shows the percentage of cells reacting to stimulation for each respective biosensor, given 
as the mean and S.D. (error bars) of cAMP response rates. These experiments were done in N1E 
cells co-transfected with the 5-HT1A receptor together with CEPAC* or EPAC from eight and seven 









4.1 Receptor crosstalk - coexpression generates novel functionality  
 
The conducted experiments allowed the investigation of 5-HT1A and 5-HT7 receptor crosstalk 
in coexpressing cells. A strong serotonergic innervation is evident in manifold human brain 
structures such as amygdala, cerebral cortex, striatum and hippocampus (Azmitia and 
Gannon 1986). 5-HT1A and 5-HT7 receptors are physiologically coexpressed in the same 
neuronal cells as shown for CA1 hippocampal neurons (Bickmeyer et al. 2002, Neumaier et 
al. 2001, Azmitia et al. 1996, Kia et al. 1996) and neurons in the prefrontal cortex in rodent 
and primate brains. Figure 1.6 illustrates 5-HT1A – 5-HT7 coexpressing cells in the pre-
Bötzinger complex of the ventrolateral medulla of the brainstem (Kindly provided by Dr.Dr. 
Till Manzke). Considering physiological occurrence of both receptors in the same neurons it 
is of particular interest to investigate 5-HT1A - 5-HT7 interaction with regard to their counter-
cooperative impact on the adenylyl cyclase. 5-HT1A receptors, when expressed alone, are 
known to negatively couple to AC via inhibitory Gi proteins and consequently to decrease the 
cellular cAMP concentration. 5-HT7 receptors in contrast increase [cAMP] via stimulating Gs 
proteins. Control measurements supported this paradigm for the test setup utilized in the 
current thesis (Fig. 3.6). A live imaging FRET approach was chosen so that the cellular 
[cAMP] trend could be analyzed in single living cells during stimulation in real-time. Thus, it 
was possible to deduce what impact each receptor subtype exerted when they are 
coexpressed in the same cells and which receptor pathway potentially appeared to be 
dominant. Prior to the coexpression experiments, it was necessary to prove that both 
receptors were expressed in equal amounts. This was realized by receptor labeling and 
visual selection. An additional consideration is that many GPCRs, including serotonin 
receptors 5-HT1A and 5-HT7, tend to oligomerize (Lee 2004, Woehler and Ponimaskin 2009, 
Kobe et al. 2008) which often results in altered signaling properties. Hetero-oligomerization 
of 5-HT1A and 5-HT7 might occur to varying extends, but in any case a strong functional 
interaction became evident in this analysis. The fundamental observation in this work is that 
treatment of 5-HT1A – 5-HT7 coexpressing cells with serotonin or even with the 5-HT7 
receptor specific agonist AS19 leads to a strong 5-HT1A like [cAMP] decrease (EfDA/γ 
increase) (Fig. 3.6; Fig. 3.10). The Gi mediated AC inhibition clearly presents itself dominant 
towards activation. Specific antagonists for 5-HT1A (WAY) and 5-HT7 (SB), respectively, were 
able to block this serotonin evoked AC inhibition about 92 ± 7 % and 75 ± 4 % (Fig. 3.9). 





control experiments (Fig. 3.7) excludes a mere dominance of 5-HT1A receptors in the 
coexpression model. Instead, a complex receptor interaction becomes apparent. Blockade of 
the Gi protein was performed to further track the pathway and gather additional information 
about the nature of the 5-HT1A – 5-HT7 interference. Pre-treatment of the coexpressing cells 
with the known Gi inhibitor pertussis toxin entirely blocked the signaling pathway (Fig. 3.11). 
In addition, cotransfection of a dominant inactive Gi protein mutant also diminished the 
[cAMP] decrease after 5-HT application to one third of the control value (Fig. 3.11). A model 
illustrates the newly observed signaling patterns in figure 4.1 under assumption of a potential 
5-HT1A – 5-HT7 heterodimer. It seems reasonable to suppose that the agonist and antagonist 
binding sites of both receptor subtypes are still functional in the coexpression model, since 
both specific antagonists inhibited signal transmission. In control measurements, by contrast, 
specific antagonists hardly blocked receptor activation of the other non-specific receptor (Fig. 
3.7). Nevertheless, there are now multiple possibilities that could explain the newly found 
signaling features. Coexpression might have induced a 5-HT1A – 5-HT7 receptor oligomer 
that couples to the Gi protein and can be coactivated and/or trans-inhibited. But, 
coexpression might also have changed the affinities for formerly specific agonists and 
antagonists or the selectivity for G proteins might have altered. These reflections are going to 









Fig. 4.1 Signaling properties in 5-HT1A – 5-HT7 coexpressing cells on the basis of a putative 
hetero-oligomer  
The model illustrates the observed signaling patterns in 5-HT7 and 5-HT1A receptor coexpressing cells 
under assumption of a potential heterodimer. Serotonin application in coexpressing cells leads to G i 
mediated, pertussis toxin sensitive AC inhibition and [cAMP] decrease in the following. Red lines 
indicate the assumed signaling pathways after 5-HT7 - 5-HT1A coactivation. Thick lines show common 
AC inhibition via Gi; Thin line indicates possible, residual Gs activation. Abbreviations: 5HT, serotonin; 
5-HT7/1A, serotonin receptor subtypes 7/1A; Gs, G-protein subunit αs; Gi, G-protein subunit αi; AC, 
adenylyl cyclase, AMP, adenosin monophosphate; cAMP, cyclic adenosin monophosphate.  
 
4.1.1 Oligomerization, coactivation and trans-inhibition 
 
The newly found signaling features, illustrated in figure 4.1, are the reflection of receptor 
interaction on one or more level of the downstream pathway, from activation over direct 
receptor interference to G protein-coupling and AC acquisition. Formation of a receptor 
oligomer that can be coactivated and trans-inhibited is one option that could account for the 
new observations. Many GPCRs build oligomers (Woehler and Ponimaskin 2009, Kobe et al. 
2008). 5-HT1A receptors have been shown to form homo-oligomers. As pointed out earlier, 
collaborating groups revealed that 5-HT1A and 5-HT7 also hetero-oligomerize in vitro and in 





oligomerization of GPCRs has been shown to alter signaling properties in a vast number of 
cases. Upon oligomerization conformational changes of the monomeric subunits occur and in 
doing so, affect signaling. Thus Rocheville et al. (Rocheville 2000) revealed that dopamine 
receptors D2R and somatostatin receptors SSTR5 interact physically through hetero-
oligomerization in CHO-K1 cells and therefore create a novel receptor with enhanced 
functional activity. They show that in coexpressing cells the SSTR5 agonist somatostatin-14 
is capable of activating the DR2 downstream signaling pathway and suggest that this is a 
consequence of different conformational states of the agonist- or antagonist-occupied 
receptor complex.  
Figure 3.6 reveals that serotonin application to 5-HT1A – 5-HT7 coexpressing cells leads to 
[cAMP] decrease as seen before in 5-HT1A – only expressing cells. Common activation of the 
putative 5-HT1A – 5-HT7 heterodimer as shown in the scheme above (Fig. 4.1) would, in this 
case, comparably to the observations from Rocheville et al. recruit Gi protein and 
consequently inhibit AC. However, Renner et al. (2012) revealed in GTPγS coupling assays 
(Kvachnina et al. 2005) that 5-HT1A – 5-HT7 hetero-oligomerization leads to decreased 
activation of Gi protein through 5-HT1A. These findings might differ from the results in the 
actual thesis for various reasons and are going to be discussed in 4.1.4. The ability of the 5-
HT7 specific agonist AS19 to trigger the Gi pathway in coexpressing cells (Fig.3.10) might 
constitute a similar transactivation. The AS19 experiments are going to be discussed in 
4.1.3. 
Besides that, Barki-Harrington et al. (Barki-Harrington 2003) also reported trans-inhibition of 
putative β-adrenergic receptor and angiotensin II type 1 receptor hetero-oligomers in mouse 
cardiomyocytes. Specific inhibition of one receptor could in this case efficiently prevent 
signaling of the other respective receptor. The 5-HT7 specific antagonist SB is able to block 
the Gi mediated [cAMP] descent in 5-HT1A – 5-HT7 coexpressing cells (Fig. 3.9), whereas SB 
had no effect on 5-HT1A receptors in control measurements (Fig. 3.7). This phenomenon 
might be due to trans-inhibition similar to the observations from Barki-Harrington et al. 
Similarly, 5-HT7 signaling is crucial for serotonin mediated 5-HT1A internalization, which gets 
interrupted upon SB application in coexpressing cells (Renner et al. 2012). 
These experiments could not reveal whether 5-HT1A - 5-HT7 oligomers are responsible for 
the new signaling properties. Nevertheless, there is no doubt that the two receptors, when 
expressed together, interact and display signaling patterns different from when they are 





G protein coupling selectivities could also account for the new signaling features and are 
going to be discussed below.  
 
4.1.2 Effect of coexpression on receptor pharmacology - altered agonist- and 
antagonist affinities 
 
As mentioned above, coexpression and potentially oligomerization can lead to altered 
affinities for agonists or antagonists compared to the affinities of the single receptors. Upon 
coexpression of µ-and δ-opioid receptors in COS-7 cells, George (George 2000) observed 
reduced potency and altered rank order of highly selective synthetic agonists for each, 
whereas endomorphin-1 and Leu-enkephalin showed enhanced affinity, suggesting the 
formation of a novel binding pocket. (see also Gomes et al. 2000) That raises the question 
whether the dominance of the Gi-pathway in the actual investigation can be explained by 
changed receptor pharmacology. Application of serotonin in 5-HT1A – 5-HT7 coexpressing 
cells caused a [cAMP] decrease, even slightly stronger than in 5-HT1A - only expressing cells 
(Fig. 3.6). Supposing that a change of agonist affinities was responsible for this phenomenon 
would mean that the 5-HT1A receptor had become more and the 5-HT7 receptor less affine for 
serotonin. Again, the 5-HT7 specific antagonist SB blocked the AC inhibition (Fig. 3.9). 
Consequently, there also had to be an analogue change of antagonist affinities for both 
receptors. As expected, the 5-HT1A specific antagonist WAY was able to block the AC 
inhibition too. Its blocking ability appeared slightly enhanced; 92 ± 7% upon coexpression 
versus 77 ± 7 % in 5-HT1A - single expression.  If affinity changes for agonists and 
antagonists accounted for the altered signaling properties under coexpression, multiple 
changes must have occurred. The 5-HT1A receptor subtype would have generally gained 
stronger affinities for serotonin, SB and WAY, whereas 5-HT7 binding sites would exhibit 
reduced affinities. Figure 3.7 shows the blocking abilities of SB and WAY in 5-HT7 – only or 
5-HT1A – only expressing cells. SB can block 5-HT7 receptor activation to 70 ± 6 % and 5-
HT1A receptors just to 3 ± 1 %. These results are in accordance to the literature Ki values 
(Lovell et al. 2000, Hagan et al. 2000) and confirm (SB) antagonist selectivity for 5-HT7 when 
expressed alone. WAY also appears selective, albeit for 5-HT1A of course, in these controls. 
(Chemel et al. 2006) 
5-HT1A - 5-HT7 coexpressing cells were further stimulated with 5-HT7 specific AS19, also 
leading to AC inhibition ([cAMP] decrease) (Fig. 3.10) (see 4.1.3). AS19 application in 5-HT7 





have altered their affinities for this agonist upon coexpression with the result that 5-HT1A 
gained and 5-HT7 lost affinity for AS19.  
 
4.1.3 AS19 experiments 
 
Activation of 5-HT1A - 5-HT7 coexpressing cells with the 5-HT7 receptor specific agonist AS19 
led to AC inhibition ([cAMP] decrease) to almost the same extent as with serotonin (Fig. 
3.10). Subsequently, AC inhibition is blocked by the 5-HT7 receptor specific antagonist SB to 
90 ± 7 % (Fig. 3.10, B). Hence, the same picture is repeated as with serotonin. The Gi 
mediated [cAMP] lowering appears dominant and the, usually Gs – coupled, 5-HT7 receptor 
does not seem to exert any impact. In control experiments AS19, in the used concentration 
of 100 nM, was not able to activate 5-HT1A receptors while 5-HT7 receptors displayed a 
moderate response (Fig. 3.10). The literature Ki values for AS19 are 4.6 nM for 5-HT7 and 
110 nM for 5-HT1A (Bosker et al. 2009).  Due to dilution in the measuring chamber 100 nm 
AS19 apparently was not sufficient to activate 5-HT1A receptors, but 5-HT7 receptors to a 
certain extent. At first appearance, it seems contradictory that unilateral activation elicits a 
[cAMP] decrease whereas inhibition of either receptor in prior experiments almost totally 
blocked signaling (Fig. 3.9). However, going back to the previously discussed feature of 
transactivation, this could be a result of the receptor interaction and/or oligomerization, 
respectively (Rocheville 2000) (see 4.1.1). In that case SB would similarly trans-inhibit Gi 
activation. It is also conceivable that the receptors change their affinities for AS19 upon 
coexpression/oligomerization as discussed above (see 4.1.2). 5-HT1A receptors would then 
have become more and 5-HT7 receptors less affine for AS19. Consequently, AS19 could 
activate 5-HT1A and trigger the Gi protein pathway.  
 
4.1.4 Diversity in G protein-coupling  
 
5-HT1A – 5-HT7 coexpressing cells respond to serotonin or AS19 application with [cAMP] 
decrease (see Fig. 3.6, Fig.3.10, and 4.1.1 - 4.1.3). In the previous chapters features like 
transactivation, trans-inhibition or changed agonist affinities have been discussed as reason 
for this Gi pathway dominance. Usually 5-HT1A receptors couple to Gi and 5-HT7 to Gs. 
However, coexpression of 5-HT1A and 5-HT7 might have altered their G protein-coupling 





Principally, many GPCRs have the ability to transduce signal through a variety of G proteins. 
The 5-HT4-receptor for instance is described to couple to Gi and Gs (Pindon et al. 2002). 
Additionally, oligomerization can modify G protein-coupling selectivity. Barki and Harrington 
(2000) revealed, that hetero-oligomerization of β-adrenergic receptors and angiotensin II type 
1 receptor in mouse cardiomyocytes can lead to a covering of G protein binding sites. They 
assume that blocking of either βARs or AT1Rs in the putative heterodimer induces a 
conformational change that is no longer favorable to support the interaction of the other 
receptor with its G protein. Moreover, oligomerization can generate novel G protein binding 
sites distinct from those of their constituent receptors (Lee 2004). Similarly, a potential 5-
HT1A - 5-HT7 receptor oligomer might exhibit a changed G protein-coupling profile compared 
to the single receptors. Since 5-HT activation of the putative 5-HT1A - 5-HT7 receptor oligomer 
in the actual study induces AC inhibition ([cAMP decrease]), it seems likely that the majority 
of the oligomers are coupled to Gi not to Gs. Upon blockade of Gi protein-coupling to the 
receptors, using pertussis toxin (PTX) or transfection of a dominant inactive Gi mutante (Fig. 
3.11), the [cAMP] decrease is totally absent or reduced to one third, respectively. It is 
therefore evident that the effect is Gi mediated. The number of remaining bound Gs is 
obviously not high enough to activate AC, as no [cAMP] increase was detectable after 5-HT 
application. It can therefore be assumed that the putative oligomer might possess a minor 
affinity for Gs and a higher affinity for Gi. However, Renner et al. (2012) found a decreased 
activation of Gi through 5-HT1A, when coexpressed with 5-HT7, in GTPγS coupling assays. 5-
HT7 mediated Gs activation in contrast seemed not to be affected. These contradictory 
findings to the results shown above (Fig. 3.6) could have different reasons. It is conceivable 
that the different protocols and approaches accounted for the difference. All coexpression 
experiments in this thesis have been conducted in presence of 100 nM forskolin in order to 
elevate the cellular [cAMP] to a mean level. Different initial [cAMP] values could lead to either 
blunted or enhanced coupling of Gi. Moreover, Renner et al. used GTPγS proteins to 
examine G protein coupling whereas in this thesis [cAMP] was measured after receptor 
stimulation, which constitutes another endpoint of the signaling cascade. The use of GTPγS 
and antibodies directed against G proteins could yield different results as the pure measuring 
of [cAMP]. On the other hand, it is possible that the results do not interfere, but that the here 
presented decrease in [cAMP] is not consequence of enhanced Gi activation by 5-HT1A but of 
additional Gi coupling to 5-HT7, disturbed Gs activation of AC or potential effects of the G 
protein βγ-subunits (also see 4.3). Renner et al. (2012) also report augmented 5-HT1A 
internalization upon 5-HT1A-5-HT7 hetero-oligomerization. Similarly, one would expect a 
diminished role of 5-HT1A under these circumstances. It is again feasible that 5-HT1A 





more effectively succeed in recruiting Gi proteins. Additionally, Renner et al. (2012) reveal 
synergistic interaction of 5-HT1A and 5-HT7 when they show that heterodimerization 
increases the 5-HT1A mediated phosphorylation of the MAP kinase Erk1.  
 As mentioned above a further possibility for the here presented dominance of the Gi 
pathway in the 5-HT1A - 5-HT7 coexpression model is additional Gi coupling to the 5-HT7 
receptor. In this case both receptors would couple to Gi and 5-HT7 receptor agonists and 
antagonists could influence the Gi pathway as well. Nevertheless, a mere additional Gi 
binding to 5-HT7 could not explain that the 5-HT1A specific antagonist WAY and the 5-HT7 
specific antagonist SB both blocked the [cAMP] decrease to 92 ± 7 % and 75 ± 4 %, 
respectively. The not-blocked other respective receptor would still activate Gi proteins. 
Consequently, the total [cAMP] decrease would be lowered but presumably not on this scale, 
especially considering that each antagonist blocked its specific receptor to an even lesser 
extent in control measurements. (Fig. 3.7)  
The stoichiometry between GPCRs and G proteins might also have an influence on 
signaling.  Homodimers of human leukotriene B4 (LTB4) receptors BLT1 bind only to one G 
protein (Banères and Parello 2003). Such a 2 : 1 - R : G protein stoichiometry could also 
exist in the case of the putative 5-HT1A - 5-HT7 receptor oligomer. Cases have been reported, 
in which only one subunit of a dimer binds to a G protein, whereas the other one serves as a 
docking platform and loses its coupling ability (Filipek et al. 2004). In a potential 5-HT1A – 5-
HT7 dimer, 5-HT7 might have lost its coupling ability to Gs.  
Renner et al. (2012) showed that oligomerization of 5-HT1A and 5-HT7 happens regularly in 
vitro and in vivo and that 5-HT7 receptors possess a higher potential to form homodimers 
than for 5-HT1A and 5-HT7 to heterodimerize. Altough, heterodimerization occurs more often 
in the lux-FRET based dimerization model than 5-HT1A homodimerization. It is therefore 
more likely, that the altered signaling behavior, presented in this thesis, is the result of 
interaction in a putative heterodimer than of 5-HT1A homodimers. Nevertheless,it is still 
possible, that homodimers play a role in the observed processes. Homodimerization of 5-
HT1A, even if less often could be responsible for the Gi dominance. On the other hand, even 
5-HT7 dimers could, assuming a changed signaling bahvior compared to monomers, account 








4.2 Coexpression analysis, receptor distribution and fluorescence labeling 
 
To examine the interaction of the two serotonin receptor subtypes 5-HT1A and 5-HT7 in this 
coexpression model, it is important to have an equal expression of both in the investigated 
cells.  
Visual selection via fluorescence receptor labeling was performed prior to all FRET 
experiments to analyze only these cells which coexpressed both receptors, as possible in 
equal shares (Fig. 3.2). Fig. 3.8 illustrates that 5-HT1A receptors exhibited weaker EfDA/γ 
response to serotonin when tagged to mCherry. When marked with fluorescent quantum dots 
in contrast the responses were as strong as in the controls. 5-HT7 receptors seemed not to 
be affected by mCherry tags in their ability to decrease EfDA/γ (increase cAMP). 
Consequently, 5-HT7 receptors were labeled with mCherry and 5-HT1A receptors with QDs in 
further coexpression experiments. It was nonetheless not possible to determine the exact 
receptor distribution and percentage of each receptor in every single measured cell. 
However, FACS analysis of cells, transfected with fluorescence labeled 5-HT1A or 5-HT7 
receptors in equal amounts, revealed virtually no difference in receptor expression 
(Experiments were conducted by Dr. Marcus Niebert) (Fig. 3.1). Moreover, functional 
analysis showed the influence and consequently the presence of both receptors in 
coexpressing cells in functionally significant amounts. Both antagonists, the 5-HT1A selective 
WAY and the 5-HT7 selective SB, were able to block 5-HT induced [cAMP] decrease in 
coexpressing cells (Fig. 3.9). The block was even more effective than in cells which 
expressed only each respective receptor alone (Fig. 3.7)(see also 4.1.4). In these control 
measurements each antagonist was hardly able to inhibit the nonselective receptor so that 
unselectivity of the antagonists is not the reason for the strong blocking abilities in 
coexpressing cells (Fig. 3.7). It is therefore evident that both receptors are present in 
coexpressing cells in sufficient amount to have an effect on [cAMP] (see also 4.1.2). 
Furthermore, this functional verification actually proofs receptor presence in the membrane 
and not in the cytosol because antagonists do not pass the membrane.  
Taken together all this evidence strongly suggests a balanced expression of both receptors 
in measuring cells.  
One more observation supports the theory of equal receptor expression. As mentioned 
above fluorescent antibodies unambiguously confirmed the presence of both receptors in 
each analyzed cell. However, since the Gi pathway in coexpression experiments appears 





expressed than 5-HT7 in these cells. There is one more important fact, alongside all the other 
measures, that contradicts this assumption. After 5-HT application, the cells demonstrated, 
as already noted, a strong [cAMP] decrease. Specific 5-HT1A receptor inhibition in these cells 
did not result in an overshooting cAMP production. If just a higher expression of 5-HT1A was 
responsible for the Gi pathway dominance, one could expect a raise of the cAMP production 
by the remaining 5-HT7 receptors after total 5-HT1A inhibition. Again, 5-HT7 receptors alone 
considerably increased [cAMP] (Fig. 3.6). Instead, the total [cAMP] trend is still negative after 
5-HT1A blockade (Fig. 3.9). But since 5-HT7 receptors had previously been identified optically 
in these cells, there has to be another reason for the Gi dominance as discussed in 4.1 – 
4.1.4.  
 
4.2.1 cAMP microdomains 
 
The distribution of receptors in the cellular plasma membrane has major impact on signaling. 
Many studies have shown that GPCRs localize in certain cholesterol-rich compartments or 
microdomains for fast and efficient signal transduction (Foster et al. 2003). It has been 
suggested that these microenvironments, also known as lipid rafts, contain exchangeable 
sets of signaling elements and therefore favor specific protein-protein interactions and 
subsequent pathway modifications (Simons and Toomre 2000). There is unequivocal 
evidence that compartmentalized cAMP signaling occurs (Agarwal et al. 2011, Steinberg and 
Brunton 2001, Lingwood and Simons 2010) and 5-HT1A and 5-HT7 receptors might also 
cumulate in such microdomains. The close proximity in these areas might likewise favor 
oligomerization of the two receptors. However, the FRET method in the actual thesis gathers 
the averaged signal of the entire cell. Throughout the whole cell, cAMP triggers the 
conformational change of the FRET sensor and the microscope measures the fluorescence 
of membrane associated and cytosolyc compartmens. Consequently, the acquired data 
contain areas with high and others with low density of the expressed 5-HT receptors. 
Measuring of distinct cAMP microdomains close to the membrane might even deliver 









4.3 Signal transmission and crosstalk by G protein-βγ subunits 
 
In the present investigation it has been shown that serotonin activation of 5-HT1A - 5-HT7 
receptor coexpressing cells diminishes the cellular cAMP concentration (Fig. 3.6). Other 
studies suggested that the Gβγ subunits of heterotrimeric G proteins might, in addition to Gα 
subunits, stimulate or inhibit the cAMP forming enzyme adenyly cyclase (Nielsen et al. 1991). 
This conclusion would mean that the [cAMP] decrease after serotonin application in 5-HT1A – 
5-HT7 coexpressing cells might as well be induced by Gβγ instead of Gi. However, these 
findings were made under very special conditions and therefore a major impact of Gβγ on AC 
can be excluded for the current thesis. Besides, Renner et al. (2012) rather report diminished 
function of Gβγ subunits upon 5-HT1A-5-HT7 hetero-oligomerization since interaction of the 
two receptors markedly decreased activation of G-protein-gated inwardly rectifying 
potassium (GIRK or Kir3) channels by 5-HT1A.  
When Gα subunits of G proteins get activated, Gβγ units dissociate, trigger targets on their 
own and reassociate with Gα units to enter a new signaling cycle. In contrast to receptor - Gα 
coupling, there is little selectively between Gα and Gβγ coupling, resulting in a shared pool of 
these subunits (Woehler and Ponimaskin 2009). 
In 1991 Nielsen et al. revealed that in insect ovarian Sf9 cells Gβγ subunits of G proteins were 
able to either inhibit or stimulate AC dependant on the AC subtype (calmodulin-sensitive vs. 
not calmodulin-sensitive) (Nielsen et al. 1991). Nevertheless, these effects occurred only in 
the presence of recombinant Gsα (rGsα) activated with guanosine-5´-O-(3-thiotriphosphate) 
(GTP-γ-S). GTP-γ-S binds to Gsα with high affinity and subsequently prevents Gβγ from 
reassociating with Gsα. Consequently, Gβγ subunits accumulate and then reach very high 
concentrations at which they are able to influence AC. Since reassociation of Gβγ subunits 
with Gα was not blocked in our present experimental conditions, such extreme concentrations 
of Gβγ as described in Nielsen et al. 1991 are highly improbable. Furthermore, specific 
blockade of the G protein α subunit Gi with pertussis toxin inhibited the entire [cAMP] 
decrease (Fig. 3.11), suggesting a principle role for Gi rather than Gβγ in transducing the 5-
HT signal. Since Gs and Gi share the same pool of Gβγ subunits, which are available to both 
of them without preference, Gβγ cannot account for the Gi dominance.  
In conclusion, Gβγ subunits are not responsible for the newly found signaling features upon 5-







4.4 Test setup 
 
As has been pointed out above, FRET imaging is a very comfortable way to measure 
changes in cellular cAMP concentrations in high temporal and spatial resolution. The 
principles of FRET measurements as well as the conversion of recorded EfDA/γ values to 
apparent [cAMP] values after cAMP calibration are to be found in chapter 2.1 and following. 
Optimal excitation and emission wavelengths were adjusted for respective filter sets in 
previous studies (Salonikidis et al. 2008). Hence, the different excitation lights and recorded 
emission lights do not unintentionally interfere with each other in terms of artefacts (see 
2.1.5). All recorded FRET values are corrected for the donor bleedthrough, the inevitable 
donor emission fraction in the emission light of the acceptor filter set (see 2.1.3). 
Furthermore, special care was taken that the receptor labeling fluorophores do not interfere 
with each other or with the FRET fluorophores. Fig 2.5 shows the distinct emission spectra of 
the fluorescent dyes mCherry and quantum dots, which mark 5-HT7 and 5-HT1A receptors, 
respectively. This allows explicit differentiation and illustration of both receptors in different or 
within the same cells when using appropriate filter sets.  
The EfDA/γ values were recorded during stimulation and inhibition of 5-HT1A and 5-HT7 
expressing cells, while agonists and antagonists were applied into the cell solution bathing 
chamber. In this respect, it was difficult precisely to investigate differences in the stimulation - 
response delays between the two receptors. Kinetic measurements were performed to find 
out if activation of the receptors might be in consecutive order. Figure 3.5 depicts the 
intervals between agonist application and detectable effect, depending on the receptor and 
the used biosensor (see 3.2.1). A illustrates the results with a bigger bathing chamber that 
held about 1500 µl. The delays between agonist application and receptor response ranged 
from 16 to 62 seconds in average and displayed no logical pattern of a faster or a slower 
receptor. B shows the results with a smaller optimized chamber with a volume of 500 µl 
which was installed to increase the solution exchange speed. With the new chamber the 
delays averaged about 9 s for both receptors. A faster solution application approach might 
reveal a consecutive activation of the two receptors but was not feasible for the used setup 
as cells were prone to wash away from the cover slips. A difference in the stimulation – 







4.5 Conclusion and outlook 
 
In FRET measurements coexpression of the two serotonin receptors 5-HT1A and 5-HT7 
revealed a strong, complex interaction. The fundamental observation is that stimulation of 5-
HT1A – 5-HT7 coexpressing cells with serotonin leads to a [cAMP] decrease as seen before in 
5-HT1A - only expressing cells. The Gi mediated adenyly cyclase inhibition appears clearly 
dominant towards Gs mediated activation. With the help of receptor labeling and visual 
selection combined with supporting FACS measurements and functional analysis it can be 
excluded, that the observation is due to imbalanced expression of the two receptors. The 
blocking experiments showed that specific blockade of either receptor almost completely 
inhibits the 5-HT signal transduction in coexpressing cells, indicating the functional influence 
of both receptors. Blockade of the G protein confirmed that the AC inhibition is Gi mediated. It 
was stunning that even application of the 5-HT7 specific agonist AS19 elicits the same 
[cAMP] decrease that one would have expected upon 5-HT1A activation. It became apparent 
that 5-HT1A – 5-HT7 coexpression generates entirely novel signaling properties as compared 
to the single receptors.  
In a vast number of cases coexpression has been reported to alter signaling features of 
several receptors (George 2000, Gomes et al. 2000, Rocheville 2000, Barki-Harrington 
2003). Many times it has been shown that actual receptor oligomerization creates new 
receptor functionality with altered pharmacology or signaling properties (Lee 2004, Woehler 
and Ponimaskin 2009, Renner et al. 2012). Therefore, different models of crosstalk have 
been discussed that could account for the newly observed signal behavior in 5-HT1A – 5-HT7 
coexpressing cells.  
Many serotonin receptors, including 5-HT1A and 5-HT7 (Kobe et al. 2008, Renner 2012) tend 
to oligomerize. That suggests the idea of a 5-HT1A – 5-HT7 hetero - oligomer that can be (co-) 
transactivated and trans – inhibited as it has been reported in many similar cases (Rocheville 
2000, Barki-Harrington 2003) (Fig. 4.1). However, the other possible explanations cannot be 
excluded according to the testing so far. Hence, altered G protein coupling selectivities and 
agonist and antagonists affinities also have to be considered as feasible reasons for the new 
observations. Even though, these two possibilities require multiple, simultaneous changes 
and therefore seem less likely.  
Further investigation is needed to clarify the exact nature of the 5-HT1A – 5-HT7 interaction. It 
will have to be determined in detail under which circumstances the two receptors 





For the physiological significance also the distribution of homo- and hetero – oligomers is 
interesting. In this respect, it is also important to examine in which neuronal microdomains 5-
HT1A and 5-HT7 receptors coexist, both in concentrations that allow the described interaction 
to have an impact on physiological signaling processes. For this purpose FRET-based 
sensors can be applied that are anchored to specific membrane fractions and therefore 
measure the cAMP production in certain membrane associated compartments (Warrier et al. 
2007). To find out if 5-HT7 receptors also couple to Gi upon coexpression it is conceivable to 
cut off the G protein binding sites and monitor if this modification changes the 5-HT signal.  
Furthermore, it is interesting if similar observations can be made with other serotonin 
receptor pairs.  
However, even if the exact nature of 5-HT1A – 5-HT7 interaction is yet to be understood, a 
strong functional interaction became evident and gives rise to further investigation of 
serotonin receptor crosstalk. Such types of receptor crosstalk are a universal feature of 

















5 Summary  
Receptor crosstalk is a universal feature of signaling and interference happens on manifold 
pathway junctions. The physiological occurrence of the two serotonin receptor subtypes 5-
HT1A and 5-HT7 in the same neuronal cells gave rise to the question of how their counter-
cooperative impact merges on the mutual target adenylyl cyclase (AC). 5-HT1A receptors are 
generally known to decrease the cellular cAMP concentration via Gi mediated AC inhibition. 
In contrast, 5-HT7 receptors commonly increase [cAMP] via AC stimulating Gs proteins. 
Förster resonance energy transfer (FRET) measurements were performed in 5-HT1A – 5-HT7 
coexpressing cells to track cAMP development during stimulation in real time. Fluorescent 
receptor labeling and visual selection of the measuring cells, combined with supporting 
FACS data and functional analysis ensured equal receptor expression in analyzed cells. An 
additional consideration is that many serotonin receptors, including 5-HT1A and 5-HT7, tend to 
oligomerize. Oligomerization has been shown to alter signaling in a vast number of cases 
and might play a key role in the 5-HT1A – 5-HT7 interaction. Coexpressing cells were 
stimulated with serotonin to examine what impact the common receptor expression had on 
[cAMP] and if one pathway appeared to be dominant. Subsequent specific inhibition of either 
receptor was supposed to review respective binding sites and further reveal the nature of 5-
HT1A – 5-HT7 interaction. Blocking on the G protein level allowed analysis of the last step of 
the 5-HT pathway before the preliminary end target, AC. The key results of the actual thesis 
are summarized below: 
1. Upon 5-HT1A – 5-HT7 coexpression a strong functional interaction with dominance of 
the Gi pathway became apparent. Coactivation of coexpressing cells leads to 
significant [cAMP] decrease.  
2. Specific blockade of either receptor almost totally prevents 5-HT signaling in these 
cells. 
3. Specific 5-HT7 stimulation likewise induces a [cAMP] decrease. 
Oligomerization of the two serotonin receptors might be a possible explanation for the newly 
observed signaling features. The available results cannot predict with certainty whether 
oligomerization occurs or not, but in any case a strong interaction became evident and gives 
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